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histone demethylase. Moreover, mutant IDH was sufficient for in vitro transformation and in vivo
tumorigenesis and its malignant potential could be attributed to epigenetic gene silencing through DNA
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mechanism by IDH mutations and suggest that both normal and neomorphic metabolite levels contribute
to chromatin structure and transcriptional regulation.
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ABSTRACT
EPIGENETIC BASIS FOR THE ONCOGENIC POTENTIAL OF IDH MUTATIONS
Chao Lu
Craig B. Thompson
Roger A. Greenberg

Although many complex diseases including cancer manifest aberrant cellular metabolism
and chromatin structure, the molecular connection between two processes remains poorly
understood. The metabolite, α-ketoglurate (αKG), is a critical co-factor for a number of
chromatin modifying enzymes. Its structural analogue, 2-hydroxyglutarate (2HG), was
recently identified as the product of cancer-associated mutations in isocitrate
dehydrogenases (IDH). To determine whether metabolic perturbation can disrupt
chromatin remodeling and transcription, I investigated the epigenetic consequences of
2HG-producing IDH mutations. In this thesis, 2HG was demonstrated to be a competitive
inhibitor for αKG-dependent chromatin modifiers including TET family DNA
hydroxylases and jumonji-C histone demethylases. Expression of mutant IDH in cell
lines led to global increases in histone and DNA methylation. In patient tumor samples,
IDH mutations were tightly associated with DNA and histone hypermethylation and were
mutually exclusive with loss of function mutations in TET2. Importantly, IDH mutation
impaired cell differentiation which could be phenocopied by exogenous 2HG or depletion
of 2HG-inhibitable TET2 or histone demethylase. Moreover, mutant IDH was sufficient
for in vitro transformation and in vivo tumorigenesis and its malignant potential could be
v

attributed to epigenetic gene silencing through DNA hypermethylation. Collectively, the
data presented in this thesis provide insight into the tumorigenic mechanism by IDH
mutations and suggest that both normal and neomorphic metabolite levels contribute to
chromatin structure and transcriptional regulation.
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Chapter 1
Introduction

Parts of this chapter have previously been published in: Lu C, Thompson CB. Metabolic
regulation of epigenetics. Cell Metab 2012 16:9-17.
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Metabolic regulation of epigenetics: a concept
Cells, whether as unicellular organisms or within a multicellular organism, need to make
various “decisions” throughout their lifetime. Every choice—quiescence, proliferation,
differentiation or migration—is made in the face of the constantly changing environment.
Metazoan cells have developed elegant mechanisms to sense and integrate extracellular
information into an intrinsic signaling system that regulates transcription so that
variations in the form of growth factors, hormones, and stromal interactions can be
registered and responded to in a timely and accurate manner. Studying these mechanisms
remains a major focus of biological research and has profound implications in
understanding human physiology and diseases.
One of the most exciting advances over the past 15 years is the field of epigenetics
(meaning “above” genetics). We now know that in addition to primary DNA sequence
information, much of the information regarding when and where to initiate transcription
is stored in covalent modifications of DNA and its associated proteins. The patterns of
various modifications along the chromatin, such as DNA cytosine methylation and
hydroxymethylation, and acetylation, methylation, phosphorylation, ubiquitination, and
SUMOylation of the lysine (K) and/or arginine (R) residues of histones are thought to
regulate the genome accessibility to transcriptional machinery. For example, acetylation
of histone lysine residues and methylation of H3K4, H3K36, and H3K79 are associated
with active transcription while methylation of DNA, H3K9, H3K27, and H4K20
generally indicates silenced chromatin. In many instances, such information is heritable.
The complexity and dynamics of epigenetic modifications are considered to provide a
link between the extracellular environment and nuclear transcription. It is increasingly
2

appreciated that many growth factor/hormone-responsive signaling pathways such as
Notch and TGFβ, often in conjunction with downstream transcription factors, can
remodel the epigenome through expressing, recruiting or editing enzymes that modify
chromatin (Mohammad and Baylin, 2010). One good example is the Notch effector RBPJ: depending on the presence of activated Notch, RBP-J recruits distinct histonemodifying enzymes to activate or repress target gene expression (Liefke et al., 2010).
A less studied but recently emerged concept is that information about a cell's metabolic
state is also integrated into the regulation of epigenetics and transcription (Figure 1.1). It
is now appreciated that cells constantly adjust their metabolic state in response to
extracellular signaling and/or nutrient availability (Vander Heiden et al., 2009). As a
classical example, while quiescent cells fully oxidize glucose to carbon dioxide in the
mitochondrial electron transport chain; proliferative cells and tumor cells consume much
larger quantities of glucose, secreting excess carbon as lactate even when oxygen is
abundant, a process termed “aerobic glycolysis.” Connections between metabolism and
transcription are not unexpected. As discussed later, in unicellular organisms like yeast
the major determinant of cell fate is nutrient levels. Even in metazoans where most
cellular signaling events are dictated by growth factors, cytokines or hormones,
metabolism still plays a significant role in transcription. This also has a potentially
unifying logic, as most chromatin-modifying enzymes require substrates or cofactors that
are intermediates of cell metabolism. It is not difficult to imagine that fluctuation of
metabolite levels could modulate the activities of chromatin-modifying enzymes and
therefore influence chromatin dynamics. As many complex diseases such as cancer and
type II diabetes display abnormalities of cellular metabolism and epigenome,
3

Figure 1.1: Signaling and metabolic inputs into epigenetics.
Growth factors, hormones and cytokines activate the classical signaling pathways and
downstream transcriptional factors which will recruit chromatin-modifying enzymes to
local chromatin. On the other hand, nutrient levels and cell metabolism will affect levels
of the metabolites which are required substrates of chromatin-modifying enzymes that
use these metabolites to post-translationally modify both histones and DNA. Variations
in these two inputs will determine the epigenome remodeling and transcription.
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understanding the molecular connections between these processes may have therapeutic
implications.
Metabolites drive oscillatory gene expression in yeast
Most laboratory strains of budding yeast Saccharomyces cerevisiae are cultured in
medium with abundant nutrients. As unicellular organisms, yeast under such conditions
uptake extracellular nutrients avidly and exploit nutrient capture to fuel cell growth and
proliferation at a logarithmic rate. However, under conditions where one or more
nutrients are limiting, yeast tend to display oscillatory metabolic behavior with distinct
phases characterized by robust changes in oxygen consumption (Chance et al., 1964).
These metabolic oscillations can vary from minutes to hours depending on yeast strains
and experimental conditions and are independent of cell division cycle (Slavov et al.,
2011). Remarkably, when genome-wide gene expression in yeast under such culture
system was analyzed, nearly 60% of the genes were expressed in a similarly cyclic
fashion (Klevecz et al., 2004; Tu et al., 2005).
These data suggest that metabolite levels might be contributing to the temporal control of
gene expression. This is supported by the observations that transient administration of
metabolites, particularly the glycolytic intermediates, could initiate phase advancement in
the oscillatory cycle (Cai et al., 2011; Tu and McKnight, 2009). Levels of acetyl-CoA,
the product of glycolytic metabolism and a donor to histone acetylation reactions, were
found to oscillate dynamically and peak during the oscillatory growth phase (Cai et al.,
2011; Tu et al., 2007). Genome-wide analysis of H3K9 acetylation showed that its
enrichment at genes expressed during growth phase correlated with acetyl-CoA levels
5

and was dependent on the generation of acetyl-CoA. Therefore it appears that levels of
acetyl-CoA can be instructive for cells to engage growth at least in part through
modulating histone acetylation and transcription of growth genes. Such a mechanism may
well operate at other times. For example, the exit of yeast from quiescence has been
reported to require glucose catabolism but not cell cycle signaling (Laporte et al., 2011).
Histone acetylation is responsive to glucose metabolism in human cancer cells
Unlike yeast, metazoan cells lack the autonomous ability to uptake and metabolize
nutrients. Instead cellular nutrient uptake is under the control of a mixture of growth
factor, paracrine and hormonal signaling. These factors control the positions that
differentiated cells can survive in the body and dictate the share of the body’s resources a
cell can utilize in maintaining itself.
However, arguably the most fundamental hallmark of cancer cells is the sustained growth
and proliferation which are independent of growth factors and hormones (Hanahan and
Weinberg, 2011). This can be achieved through activating mutations and amplifications
in the mitogenic signaling pathways (e.g. PI3K and RAS), and/or suppression of negative
growth regulators (e.g. PTEN). As a result, similar to yeast cancer cells possess a
constitutively active anabolic metabolism and avidly take up nutrients in the environment
to ensure maximum growth and proliferation. This observation has been clinically
applied as the use of positron-emission tomography (PET) to image the uptake of a
glucose analogue 18F-2-deoxyglucose by tumor cells (Vander Heiden et al., 2009).
Moreover, before sufficient generation of tumor-associated neovasculature, cancer cells
often experience dramatic variations in extracellular nutrient levels. Therefore it is
6

plausible that in cancer cells metabolic state may influence gene expression and cell
behavior through the regulation of epigenetics. Consistent with this notion, compared to
normal tissues tumors often show aberrant epigenome profiles which are thought to be
critical for their initiation, progression and maintenance (Baylin and Jones, 2011).
A landmark paper by Wellen et al. confirmed the above hypothesis by demonstrating the
link between glucose metabolism and histone acetylation in colon cancer cells (Wellen et
al., 2009). In mammals, most cytosolic acetyl-CoA comes from citrate exported from
mitochondria by a reaction catalyzed by ATP-citrate lyase (ACL) (Figure 1.2). Wellen et
al. found that a fraction of ACL is localized in the nucleus and knocking down ACL
substantially reduced the levels of histone acetylation. As a result, the expression of
glucose metabolism genes was affected and cells with diminished ACL showed defects in
growth, proliferation and differentiation. This study suggests that chromatin states are
sensitive to the fluctuation of metabolite levels, which may represent an important
mechanism for tumor cells to adapt to their microenvironment. However, it remains to be
explored whether other metabolites in addition to acetyl-CoA contribute to regulatory
events at the chromatin.
Histone and DNA demethylation are important chromatin events and require αKG
The methylation of 5’ position of cytosines in DNA is probably the most studied
epigenetic modification so far. In mammals, cytosine methylation occurs mainly at the
CpG dinucleotides. Most CpG sites are present at repetitive elements of the genome and
constitutively methylated, however they are also found at gene promoters as clusters
known as “CpG islands”. Importantly, while in normal tissues CpG islands are mostly not
7

methylated, tumor cells display hypermethylation at these sites (Baylin and Jones, 2011).
DNA hypermethylation at gene promoters correlates with transcriptional repression and it
is believed that DNA hypermethylation initiates/promotes tumorigenesis through
silencing tumor-suppressor genes. Supporting this notion, inhibitors of DNA
methyltransferases, the enzymes responsible for adding the methyl group to cytosines, are
approved as anti-leukemia agents in clinic.
In addition to acetylation, histone lysine residues can also be methylated (Klose and Zhang,
2007). While histone acetylation generally correlates with transcriptional activation, histone
methylation contributes to both transcriptional activation and repression. In general,
methylation of H3K4, H3K36 and H3K79 indicates active chromatin while methylation of
H3K9, H3K27 and H4K20 is associated with repressed chromatin. Moreover, each lysine
residue can be modified into mono- (me1), di-(me2), or tri-(me3) methylated state. The
complex patterns of histone methylation, together with acetylation and other modifications
such as phosphorylation and SUMOylation, are thought to provide a so-called “histone code”
to be recognized by specific “reader” proteins to initiate downstream chromatin remodeling
events (Strahl and Allis, 2000). The role of histone methylation in cancer is poorly
understood and likely to be tissue-specific.

A covalent methyl group is chemically stable. Therefore DNA and histone methylation
were considered as relatively static epigenetic marks. However during embryonic
development there is extensive remodeling of the cellular methylome, suggesting the
existence of enzymes that actively remove methylation marks. Indeed in recent years, a
variety of histone demethylases (HDMs) and DNA hydroxylases (DNHDs) have been
identified. A family of HDMs named Jumonji-C domain containing HDM (JHDM) was
8

shown to remove methylation from histones through a reaction that utilizes αKG, oxygen
and Fe (II) as co-factors and releases succinate and formaldehyde as by-products
(Tsukada et al., 2006). Similar mechanism was adopted by the newly identified TET
family enzymes that hydroxylate the 5-methylcytosine of DNA (Tahiliani et al., 2009).
The only difference is that in this reaction, the hydroxymethyl group is a stable product
and further TET-dependent modification is undertaken with low stoichiometry (He et al.,
2011). The function of 5-hydroxymethylcytosine is the topic of intensive investigation
and thought to serve as an intermediate for subsequent active (TET-dependent) or passive
(replication-dependent) demethylation (He et al., 2011; Tahiliani et al., 2009). Notably,
loss-of-function mutations in members of JHDM and TET families have been identified
in various malignancies (Delhommeau et al., 2009; van Haaften et al., 2009).
From metabolic perspective, the demethylation mechanism by JHDMs and TETs is
interesting as it requires αKG, a key metabolite in TCA cycle and a starting point for
many anabolic pathways (Figure 1.2). αKG can be derived from glutamine through two
deamination reactions; it is also an intermediate metabolite of glucose metabolism. Since
glucose and glutamine are the two most abundant and important nutrients used by cells, it
is plausible that αKG may be a critical messenger to relay information about nutrient
state to chromatin through modulating the demethylation efficiency of histone and DNA
demethylases.
IDH1 and IDH2 generate αKG and are recurrently mutated in cancer
αKG can be generated through the decarboxylation of isocitrate, a reaction catalyzed by
IDH family enzymes. IDH family has three members: IDH1, IDH2 and IDH3. IDH3 is
9

known as the classical mitochondrial TCA cycle enzyme and its reaction utilizes NADH
as co-factor. In contrast, IDH1 and IDH2 use NADPH as co-factor and are structurally
very different from IDH3. The main distinction between IDH1 and IDH2 is their
subcellular localization: IDH1 is mainly cytosolic and peroxisomal and IDH2 is a
mitochondrial enzyme. The role of IDH1 and IDH2 in normal cell physiology is poorly
understood.
Recently, cancer genome sequencing projects revealed unexpected recurring somatic
mutations of IDH1 and IDH2 in ~70% intermediate-grade gliomas and ~20% of de novo
acute myeloid leukemia (AML) (Mardis et al., 2009; Yan et al., 2009). Targeted
sequencing in other tumor types also found their mutations in ~50% of central and
periosteal cartilaginous tumors (Amary et al., 2011), ~30% intrahepatic
cholangiocarcinomas (Borger et al., 2012), and ~20% angioimmunoblastic T-cell
lymphoma (Cairns et al., 2012). IDH mutations found in above-mentioned cancers are
always heterozygous and limited to R132 residue of IDH1 or R172 or R140 residues of
IDH2. This strongly suggests that IDH mutations are not loss-of-function. Although it
was originally proposed that mutant IDH1 acts as a dominant-negative enzyme (Zhao et
al., 2009), unbiased metabolomic screening and enzymatic study showed that the
mutation gives IDH1 a novel property to reduce αKG to 2-hydroxyglutarate (2HG) (Dang
et al., 2009). This neomorphic enzyme activity was also shown with mutant IDH2 as well
as less frequently observed IDH mutations in other types of cancer such as IDH1 G97D
and IDH1 R100A mutations (Ward et al., 2012; Ward et al., 2010). Although 2HG is
present in cells as a rare by-product from mitochondrial metabolism, patient samples with
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Figure 1.2: Crosstalk between metabolism and epigenetics in cancer.
In proliferative cells such as tumor cells, most citrate in the TCA cycle is exported to
cytosol where it is catabolized to acetyl-CoA by the enzyme ACL. Acetyl-CoA
generated by ACL can be used for the biosynthesis of lipid. They are also important
donors for histone acetylation. Alternatively citrate can be converted to isocitrate, which
is further metabolized to αKG by IDH1 in the cytosol and IDH2 in the mitochondria.
Enzymes that remove the methylation from histone or DNA use αKG as co-factors. IDH1
and IDH2 were found to be frequently mutated in cancer. The mutation results in the
accumulation of 2HG, a structural analogue of αKG. This thesis aims to investigate the
impact of 2HG on chromatin methylation and tumorigenesis.
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IDH mutations showed a 10-100 fold increases in 2HG accumulation, reaching absolute
concentration as high as 10-50 mM (Dang et al., 2009). Of note, levels of αKG did not
alter in tumors with IDH mutations.
Since the only difference between 2HG and αKG is that the α-keto group on αKG is
replaced by the hydroxyl group on 2HG, the two metabolites are structurally similar.
Hence 2HG-producing IDH mutations provide a great opportunity to investigate if
perturbation of αKG homeostasis in cells is sensed by histone and DNA demethylation
and leads to changes in gene expression and cell behavior. Moreover, the high
frequencies of IDH mutations in multiple types of cancer strongly suggest that they are
driver mutations; therefore this thesis also aims to determine whether IDH mutation is
indeed oncogenic and the role of epigenetic dysregulation in its transformation process.
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Chapter 2
Leukemic IDH1 and IDH2 mutations disrupt TET2 Function and result
in DNA hypermethylation

Parts of this chapter have previously been published in: Figueroa ME, Abdel-Wahab O,
Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF,
Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E,
Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL,
Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype,
disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010
18:553-67.
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Summary
Leukemia-associated IDH mutations are characterized by a neomorphic enzyme activity
and resultant 2-hydroxyglutarate (2HG) production. Here we demonstrate that 2HGproducing mutant IDH1 and IDH2 inhibit TET2, an α-ketoglutarate-dependent DNA
hydroxylases enzyme also mutated in acute myeloid leukemia (AML). Expression of IDH
in myeloid cells decreased levels of 5-hydroxymethylcytosine and induced global DNA
hypermethylation. In an AML patient cohort, IDH1/2 mutations were mutually exclusive
with loss-of-function mutations in TET2. Furthermore, either expression of mutant
IDH1/2 or Tet2 depletion increased stem/progenitor cell marker expression in
hematopoietic cells, suggesting a shared pro-leukemogenic effect. This work identifies
IDH1/2- and TET2-mutant leukemias as a biologically distinct disease subtype, and links
cancer metabolism with epigenetic control of gene expression.
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Introduction
Acute myeloid leukemia (AML) pathogenesis is characterized by recurrent chromosomal
translocations and somatic mutations that can define biologically distinct disease
subtypes. Among these abnormalities are mutations or rearrangement of genes encoding
aberrant transcription factors or cofactors that directly perturb gene expression and
disrupt cell differentiation and survival. Others include gain of function mutations of
kinases involved in transduction of growth and proliferation signals. However, in many
AML cases the identity and function of pathogenetic mutations remains obscure. Recent
genomic sequencing efforts in AML and in other malignancies have identified new
classes of oncogenic disease alleles. One recently identified class of genes mutated in
cancer is those coding for enzymes involved in citrate metabolism: cytosolic isocitrate
dehydrogenase 1 (IDH1) and its mitochondrial homolog IDH2 (Mardis et al., 2009;
Parsons et al., 2008; Yan et al., 2009). IDH1 and IDH2 lesions occur in ~70% of patients
with lower grade (grade II-III) brain tumors such as astrocytomas, as well as in secondary
glioblastomas derived from lower grade glial tumors (Parsons et al., 2008; Yan et al.,
2009). IDH1 and IDH2 mutations were subsequently observed in myeloid malignancies
including de novo and secondary AML (~15-30%), and pre-leukemic clonal malignancies
including myelodysplasia and myeloproliferative neoplasms (~5% of chronic phase and
~20% of transformed cases) (Mardis et al., 2009; Tefferi et al., 2010; Ward et al., 2010).
The mutational data in malignant gliomas and in myeloid malignancies suggest that
IDH1/2 mutations can occur early in disease pathogenesis and may drive tumorigenesis.
The precise genetic context in which IDH1/2 mutations occur is not known, nor is the
mechanism through which they contribute to the malignant phenotype. IDH1/2 mutations
15

are heterozygous, with tumors retaining one wild-type copy of the relevant IDH1 or
IDH2 allele, suggesting that the mutations are selected for an enzymatic gain of function
rather than a loss of function (Dang et al., 2009; Ward et al., 2010), and that retention of
the wild-type allele may be required for normal cellular metabolism. IDH1 and IDH2 are
NADP+-dependent enzymes that normally catalyze the interconversion of isocitrate and
alpha-ketoglutarate (αKG - also known as 2-oxoglutarate). The most common IDH1/2
mutations in AML and brain tumors, affecting R132 of IDH1 or R140 and R172 of IDH2,
have the common feature of acquiring a neomorphic enzymatic activity catalyzing the
NADPH-dependent reduction of αKG to R(-)-2-hydroxyglutarate (2HG) (Dang et al.,
2009; Ward et al., 2012). Presumably it is the production of 2HG that provides a
biological advantage that contributes to malignant transformation. As 2HG is a structural
analogue of αKG, differing only in the substitution of the alpha-keto group on αKG for a
hydroxyl group, it is plausible that generation of 2HG by mutant IDH1 and IDH2 might
impair the function of enzymes that require αKG as a substrate.
Recent epigenetic studies of large AML patient cohorts have demonstrated that aberrant
DNA methylation is a hallmark of AML (Figueroa et al., 2010b). Importantly, promoter
methylation data can be used to classify AML in distinct clusters defined by specific
patterns of methylation. Although a subset of DNA methylation signatures have been
found to be associated with known genetic mutations, specific AML subsets were
recognized solely based on their DNA methylation profiles (Figueroa et al., 2010b). It is
not currently known whether there are somatic genetic events that define any of the novel
epigenetic clusters in AML. The recent finding that glioblastomas with a methylator
phenotype are associated with cytosolic IDH1 mutations suggested a potential causative
16

link between these features, although mutations of the mitochondrial IDH2 enzyme were
not detected in this study and as such the relationship between IDH2 mutations and
epigenetic state could not be assessed (Noushmehr et al., 2010). Interestingly, loss-offunction mutations of TET2, an αKG-dependent enzyme that converts 5-methylcytosine
to 5-hydroxymethylcytosine (Tahiliani et al., 2009), were also identified in AML
(Delhommeau et al., 2009).
We report that in a cohort of AML patients, IDH1/2 mutations and TET2 mutations
showed remarkable mutually exclusivity. Consonant with the mutational data, IDH
mutants inhibited the function of TET2 and induced global hypermethylation and
increased hematopoietic stem cells marker, which is a characteristic feature of AML.
Collectively the data suggest increased cellular 2HG levels induced by mutant IDH
isoforms contribute to malignant transformation by interfering with the normal cycle of
DNA methylation and demethylation through inhibiting αKG-dependent enzymes such as
TET2.

17

Results
Mutations in IDH1/2 are mutually exclusive with mutations in TET2
Specimens (385) from a total cohort of 398 patients with de novo AML younger than 60
years of age enrolled in the ECOG E1900 clinical trial (Fernandez et al., 2009) were
subjected to DNA sequence analysis for AML-associated recurrent mutations. Highthroughput resequencing of IDH1 and IDH2 revealed IDH1 R132 mutations in 6.2% of
patients and IDH2 mutations in 8.6% of patients (6.3% R140Q and 2.3% R172K).
Patients with mutations in IDH1 or IDH2 did not differ from IDH1/2-wild-type patients
in terms of age, sex, or percentage of bone marrow blasts at diagnosis. No additional
somatic IDH1/2 mutations were found. All IDH1 and IDH2 mutations were heterozygous,
consistent with retention of the wild-type allele as previously reported. Although
mutations in IDH1 and IDH2 are thought to be mutually exclusive based on mutational
studies in malignant gliomas (Yan et al., 2009), occasional rare AML patients have been
reported with concurrent mutations in both IDH1 and IDH2 (Paschka et al., 2010). In this
large cohort of patients with de novo AML, mutations in IDH1 and IDH2 were mutually
exclusive.
TET2 is a Fe (II) and αKG-dependent enzyme known to display loss of function
mutations in AML and other myeloid malignancies (Abdel-Wahab et al., 2009;
Delhommeau et al., 2009). Recently all TET family members including TET2 were
shown to catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine (5OH-MeC) (Tahiliani et al., 2009). Although the physiological significance of 5-OH-MeC
remains to be determined, it is likely to be the intermediate in the pathway that actively
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demethylates 5-methylcytosine (Wu and Zhang, 2011). Importantly, expression of TET1
or TET2 in cellular systems results in a reduction in 5-methylcytosine levels (Ito et al.,
2010). Unlike other DNA demethylases identified so far, the hydroxylation reaction does
not involve any DNA damage, suggesting an important physiological function of TET2
in removing methylation marks.
We first examined the genetic status of TET2 in AML samples wild-type or mutant for
IDH1/2. As controls in analyzing for association with TET2 mutations, we also examined
the mutational status of 11 other genes known to be recurrently mutated in AML
(including PHF6, WT1, TP53, ASXL1, PTEN, RUNX1, KIT, NPM1, FLT3, CEBPA and
RAS) in this same cohort. There were 40 somatic TET2 mutations identified in 28/385
patients (7.3% of the ECOG patient cohort). Although only 1 homozygous TET2
mutation was observed, 11 of the 28 TET2-mutant patients had >1 TET2 mutation,
consistent with previous studies reporting biallelic TET2 mutations. Of the 40 TET2
mutations, 40% were insertions/deletions resulting in a frameshift mutation, 30% were
nonsense mutations, and 30% were somatic missense mutations. AML patients with
TET2 mutations did not differ from TET2 wild-type patients in terms of age, sex,
cytogenetic risk, or percentage of bone marrow blasts at diagnosis. TET2 mutant patients
also did not differ from TET2 wild-type AML patients in frequency of mutations in FLT3,
NPM1, or CEBPA.
In contrast to the other genes analyzed, the relationship between IDH1/2 and TET2
mutations was striking in this AML cohort. Although IDH1, IDH2, and TET2 mutations
were each identified in a significant proportion of patients in our study, there was a
statistically significant inverse correlation between IDH1/2 and TET2 mutations in AML
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Figure 2.1: IDH1/2 mutations are mutually exclusive with mutations in TET2 in de
novo AML.
(A) Circos diagram revealing relative frequency and pairwise co-occurrences of
mutations in IDH1 and IDH2 in de novo AML. (B) Circos diagram revealing relative
frequency and pairwise co-occurrences of mutations in TET2 in de novo AML. (C) Twoby-two table showing that mutations in IDH1/2 and TET2 were mutually exclusive in
AML (Left-tailed Fisher p-value: 0.009).
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(p=0.009, left-tailed Fisher’s exact test). Specifically, we did not identify a single patient
with concurrent mutations in TET2 and in IDH1 or IDH2; 0/57 IDH1/2 mutant cases
were TET2 mutant versus 28/300 IDH1/2 wild-type AML cases (Figures 2.1A-C). These
data suggest that TET2 and IDH1/2 mutations form a novel mutational class in AML, and
that IDH1/2 mutations and TET2 mutations have overlapping roles in AML pathogenesis.
IDH mutation inhibits the hydroxylation of 5-methylcytosine by TET2
TET2 has the classical features of an αKG –Fe(II) dioxygenase, and requires αKG in
order to mediate 5-methylcystosine hydroxylation (Tahiliani et al., 2009). The five
carbon dicarboxylic acids 2HG and αKG are chemically analogous. The substitution of
the keto (oxo) group on αKG to hydroxyl group on 2HG could potentially interfere with
Fe(II) binding and stabilization of the reaction intermediate. We therefore hypothesized
that 2HG produced by mutant IDH might inhibit the hydroxylation of 5-methylcytosine
by TET2. To test this hypothesis, we expressed FLAG-tagged TET2 in 293T cells.
Consistent with previous findings (Ito et al., 2010; Tahiliani et al., 2009), cells expressing
TET2 showed higher levels of 5-OH-MeC in the nucleus as detected by
immunofluorescence staining with 5-OH-MeC specific antibody. Co-transfection of
TET2 with IDH1 R132H, but not wild-type IDH1, reversed this increase in 5-OH-MeC
(Figure 2.2A). To obtain a more quantitative assessment, we also performed flow
cytometric analysis of 5-OH-MeC fluorescence intensity. Staining with an anti-FLAG
antibody allowed us to discriminate between TET2-positive and TET2-negative
populations; importantly the TET2-positive population showed a ~4-fold increase in the
5-OH-MeC fluorescence intensity. Co-transfection with R132H mutant IDH1 led to a
~40% decrease in the fluorescence intensity, while wild-type IDH1 had no significant
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Figure 2.2: Mutant IDH1 expression inhibits hydroxylation of 5-methylcytosine by
TET2.
(A) 293T cells were transiently transfected with FLAG-tagged TET2 in the absence or
presence of wild-type or R132H mutant IDH1. Global levels of 5-methylcytosine
hydroxylation were analyzed by immunofluorescence using antibody against 5-hydroxymethylcytosine (5-OH-MeC). Representative images from mock-transfected, TET2transfected, TET2 + IDH1 WT co-transfected, and TET2 + IDH1 R132H co-transfected
cells are shown. (B) Transfected cells were analyzed by flow cytometry and gated as
TET2 positive or negative by FLAG antibody. Representative gating is shown. Intensities
of 5-OH-methylcytosine staining within the TET2 positive and negative populations are
shown as histogram overlays. Data in (A) and (B) are representative of three independent
experiments.
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impact on 5-OH-MeC fluorescence intensity (Figure 2.2B). Together these data suggest
that expression of mutant IDH is able to inhibit the hydroxylation of 5-methylcytosine by
TET2.
Expression of 2HG-producing IDH mutant in cells induces a global decrease in 5OH-MeC and increase in 5-methylcytosine
We next sought to determine whether expression of mutant IDH was sufficient to alter
levels of 5-OH-MeC and 5-methylcytosine in myeloid cells. Wild-type or R172K mutant
IDH2 were stably expressed in mouse myeloid progenitor 32D cells. Expression of wildtype and mutant IDH2 protein was confirmed by Western blot (Figure 2.3A). 2HG levels
were measured by gas chromatography-mass spectrometry (GC-MS) and were only
induced in cells stably expressing mutant IDH2 (Figure 2.3B). The levels of 5-OH-MeC
and 5-methylcytosine were assessed by liquid chromatography-electrospray ionization
tandem mass spectrometry (LC-ESI-MS/MS). Results showed that expression of R172K
mutant IDH2 led to a significant decrease in global levels of 5-OH-MeC (Figure 2.3C).
Consistent with the role of TET2 in DNA demethylation, we also observed an increase in
global 5-methylcytosine levels (Figure 2.3D). These data support that 2HG-producing
mutant IDH causes changes in DNA methylation and hydroxymethylation.
Mutant IDH and TET2 depletion both increase expression of stem cell markers
To investigate the biological significance of IDH1/2 mutations, the effects of stable
expression of wild-type, R172K mutant or R140Q mutant IDH2 were examined in 32D
myeloid cells. Expression of mutant IDH2, but not of wild-type IDH2 in 32D cells
resulted in an average of ~40% increase in hematopoietic stem/progenitor cell marker C23

Figure 2.3: Expression of 2HG-producing IDH proteins alters global DNA
methylation.
(A) 32D cells were transduced with empty retroviral vector or with wild-type or R172K
mutant IDH2, selected in 2.5 µg/ml puromycin for 7 days, and then lysed to confirm
stable expression of IDH2. Tubulin antibody was used as a control. (B) Cells were
extracted for their intracellular metabolites which were then derivatized with MTBSTFA
and analyzed by GC-MS. Shown are representative gas chromatographs from wild-type
and mutant IDH2 expressing cells depicting the derivatized metabolites eluting between
31.3 and 33.5 min, including 4-oxoproline (4-oxo Pro), glutamate (Glu), and 2HG.
Metabolite abundance refers to GC-MS signal intensity. (C) and (D) DNA was extracted
from cells with stable wild-type or mutant IDH2 expression, and global 5-OH-MeC (C)
or 5-methylcytosine (D) levels were measured by LC-ESI-MS/MS. Relative intensity of
signals of three independent experiments was quantified. Error bars represent SD for
triplicate experiments.
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Kit expression (p=0.04; Figure 2.4A). Likewise, shRNA-mediated stable knockdown of
Tet2 expression resulted in a significant increase in C-Kit expression (p=0.02; Figures
2.4B). These data suggest that expression of IDH mutant or reduction in Tet2 expression
results in similar effects on enhancing stemness in hematopoietic cells.
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Figure 2.4: IDH2 mutant expression and TET2 knockdown in hematopoietic cells
impairs differentiation.
(A) 32D cells retrovirally transduced with empty vector, IDH2 WT, IDH2 R140Q or
IDH2 R172K were analyzed for C-Kit expression by flow cytometry. Intensities of
fluorescence signals are depicted as histograms. (B) Three independent shRNAs against
mouse TET2 were analyzed for C-Kit expression by flow cytometry. Intensities of
fluorescence signals are depicted as histograms.
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Discussion
We observed that IDH1/2 and TET2 mutations were mutually exclusive in a large,
genetically annotated de novo AML cohort, suggesting that these lesions may be
functionally redundant. TET2 is a member of a family of αKG-dependent enzymes that
catalyze cytosine 5-hydroxymethylation and induce subsequent demethylation of DNA
(Tahiliani et al., 2009). IDH1/2 mutations, which lead to elevated levels of 2HG, an αKG
analogue, would be anticipated to inhibit the function of TET2 and to result in DNA
hypermethylation. In support of this possibility we observed expression of IDH1/2
mutants induced an increase in global DNA hypermethylation, and inhibited TET2
induced cytosine 5-hydroxymethylation. These data suggest that TET2 and IDH1/2
mutations constitute a novel mutational class in AML which affects the epigenetic state;
we would predict that additional mutations will be identified which will be classified into
this novel “epigenetic regulator” mutational class in AML and in other malignancies.
The present data do not exclude the possibility that IDH1/2 mutant-mediated
transformation is in part mediated by TET2 independent effects. Other families of
enzymes that also require αKG for their catalytic activity, including Jumonji-C domain
histone demethylases, could be affected by accumulation of 2HG in leukemic cells.
Jumonji-C domain proteins can impair the spread of DNA methylation, alter the function
of transcription factors and demethylate various chromatin marks including gene
activation marks such as H3K4me3 and H3K36me3 (Tsukada et al., 2006) and gene
repressive marks such as H3K9me3 (Yamane et al., 2006). It will therefore be important
in subsequent studies to assess the effects of mutant IDH protein expression and 2HG
accumulation on the function of other αKG-dependent enzymes expressed in
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hematopoietic cells and on the chromatin state of normal and leukemic stem/progenitor
cells. Moreover, whether other somatic lesions influence the IDH1/2 and TET2 mutant
DNA methylation profiles awaits ongoing and future studies of AML genetic and
epigenetic lesions.
Collectively, the data suggest a new paradigm whereby oncogenic alterations in core
cellular metabolic pathways can lead to leukemic transformation by dysregulating the
epigenetic machinery in hematopoietic progenitors. Additionally, the data support the
notion that IDH1/2 mutants are a powerful leukemia driver. Since mutant IDH1/2 are
associated with a neomorphic function not characteristic of the wild-type protein, targeted
therapies that inhibit the neomorphic function of mutant IDH enzymes might reverse
epigenetic patterning, promote myeloid differentiation, and improve outcomes in
IDH1/2-mutant AML.
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Chapter 3
IDH mutation impairs histone demethylation and results in a block to
cell differentiation

Parts of this chapter have previously been published in: Lu C, Ward PS, Kapoor GS,
Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A,
Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson
CB. IDH mutation impairs histone demethylation and results in a block to cell
differentiation. Nature 2012 483:474–78.
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Summary
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified
in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel
enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. 2HGproducing IDH mutants can prevent the histone demethylation that is required for
lineage-specific progenitor cells to differentiate into terminally differentiated cells. In
tumor samples from glioma patients, IDH mutations were associated with a distinct gene
expression profile enriched for genes expressed in neural progenitor cells, and this was
associated with increased histone methylation. To test whether the ability of IDH mutants
to promote histone methylation contributes to a block in cell differentiation in nontransformed cells, the effect of neomorphic IDH mutants on adipocyte differentiation was
tested in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated
with repression of the inducible expression of lineage-specific differentiation genes and a
block to differentiation. This correlated with a significant increase in repressive histone
methylation marks without observable changes in promoter DNA methylation. Gliomas
were found to have elevated levels of similar histone repressive marks. Stable
transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in
progressive accumulation of histone methylation. Of the marks examined, increased
H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were
passaged in culture. Furthermore, the 2HG-inhibitable H3K9 demethylase KDM4C was
induced during adipocyte differentiation, and RNA-interference suppression of KDM4C
was sufficient to block differentiation. Together these data demonstrate that 2HG can
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inhibit histone demethylation and that inhibition of histone demethylation can be
sufficient to block the differentiation of non-transformed cells.
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Introduction
Isocitrate dehydrogenases (IDHs) are enzymes that interconvert isocitrate and αketoglutarate (αKG). Mutations in either cytosolic NADP+-dependent IDH1 or
mitochondrial NADP+-dependent IDH2 were found in ~80% of grade II-III gliomas, ~20%
of de novo adult acute myeloid leukemia (AML), ~56% of central and periosteal
cartilaginous tumors, ~30% intrahepatic cholangiocarcinomas and ~20%
angioimmunoblastic T-cell lymphoma (Amary et al., 2011; Borger et al., 2012; Cairns et
al., 2012; Mardis et al., 2009; Parsons et al., 2008; Ward et al., 2010; Yan et al., 2009). In
these types of malignancies, all mutations identified are heterozygous and resulted in
amino acid substitution of R132 of IDH1 or R172 or R140 of IDH2. Studies on the
structural and enzymatic activity of mutant IDHs revealed that the mono-allelic mutations
give the enzymes a novel property: instead of generating αKG from isocitrate, mutant
IDH converts αKG to 2-hydroxyglutarate (2HG) (Dang et al., 2009; Ward et al., 2012;
Ward et al., 2010). Consistent with this finding, elevated 2HG levels were detected in
tumor samples with IDH mutations (Dang et al., 2009; Ward et al., 2010). While a
common biochemical feature of cancer-associated IDH mutations has been discovered,
its cellular effects and functional role in tumorigenesis remain elusive.
In an effort to delineate the mechanism underlining IDH mutation-driven
leukaemogenesis, we performed comprehensive profiling of known recurrent genetic
mutations in specimens from a cohort of 385 AML patients. Strikingly, gain-of-function
IDH1/2 mutations were mutually exclusive with TET2 loss-of-function mutations
(Figueroa et al., 2010a). Because TET2 is an αKG-dependent enzyme that hydroxylates
5-methylcytosine and potentially involved in DNA demethylation (Ito et al., 2010;
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Tahiliani et al., 2009), we hypothesized that 2HG, the structural analog of αKG, could act
to inhibit TET2 and lead to abnormal DNA methylation. Indeed, expression of mutant
IDH in cells impaired the conversion of 5-methylcytosine to 5-hydroxymethylcytosine by
TET2 (Figueroa et al., 2010a). Moreover, IDH1/2 and TET2 mutations were associated
with an overlapping DNA hypermethylation phenotype. Consistent with our observations
in AML, IDH1 mutations in glioma were strongly associated with DNA
hypermethylation (Noushmehr et al., 2010). However, mutations of TET family members
have yet to be reported in brain tumors. Therefore it is possible that in glioma additional
αKG-dependent enzymes mediate mutant IDH’s effects on chromatin.
In addition to DNA methylation, post-translational modifications of histones are also
important for chromatin organization and regulation of gene transcription. Particularly,
histone lysine methylation is an integral part of the “histone code”. Recently a family of
histone lysine demethylases, known as Jumonji-C domain histone demethylases (JHDMs),
was shown to actively demethylate histone lysine residues (Klose and Zhang, 2007;
Tsukada et al., 2006; Yamane et al., 2006). Interestingly, JHDMs share a similar reaction
mechanism with TET2 that requires αKG as co-factor. In this study, we demonstrated a
direct role of 2HG in inhibiting JHDM, which leads to genome-wide increase in histone
lysine methylation. Consistent with the role of histone methylation in regulating cell
differentiation, we showed that mutant IDH arrested adipocyte differentiation. Gene
expression microarray analysis of glioma samples revealed a signature for IDH1/2
mutation that is enriched for genes involved in differentiation. These findings
underscored the importance of histone lysine methylation, in addition to DNA
methylation, as the target of 2HG-producing IDH mutations.
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Results
The fact that IDH mutations were identified in multiple cancers with disparate tissues of
origin suggests that 2HG-producing mutant enzymes probably affect some fundamental
cellular processes that facilitate tumor progression. To study the effects of IDH mutations,
we collected and performed gene expression microarray analysis on tumor specimens
from patients with grade II–III oligodendroglioma. Sequencing results revealed a high
frequency of IDH mutations in oligodendroglioma (33 of the samples had the R132 IDH1
mutation, 2 had the R172 IDH2 mutation and 6 were wild type for IDH1/2). Supervised
analysis found a statistically enriched gene signature in IDH-mutant samples (q value
<10%, fold change >2; Figure 3.1A) that was independent of tumor grade and recurrence
status and survived multiple testing corrections. Gene-ontology analysis identified the
regulation of astrocyte and glial differentiation as the top two functional categories
enriched in differentially expressed genes (Figure 3.1B). We previously reported that
IDH mutation may promote leukaemogenesis by expanding the haematopoietic
progenitor cell population and impairing haematopoietic differentiation (Figueroa et al.,
2010a), and that such a phenotype could be attributed at least in part to mutant IDHinduced inhibition of TET2, an α-ketoglutarate (αKG)-dependent enzyme potentially
involved in DNA demethylation (Ito et al., 2010; Tahiliani et al., 2009). Although DNA
hypermethylation has been associated with IDH mutation in glioma samples (Noushmehr
et al., 2010), no mutations in TET family members have been found in this disease. We
explored the possibility that IDH mutation may affect additional αKG-dependent
enzymes that contribute to the regulation of cell differentiation.
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Histone lysine methylation is an integral part of the post-translational modifications of
histone tails that are important for chromatin organization and regulation of gene
transcription (Klose and Zhang, 2007). In vitro 2HG can competitively inhibit a family of
αKG-dependent Jumonji-C domain histone demethylases (JHDMs) (Chowdhury et al.,
2011; Xu et al., 2011). To determine whether IDH-associated changes in histone
methylation could be observed in cells, we ectopically expressed wild-type or mutant
IDH1 or IDH2 in 293T cells and found that mutant IDH1 or IDH2 led to a marked
increase in histone methylation compared to the wild-type enzymes. Transient
transfection of wild-type IDH2 can also lead to increased 2HG production. In all of the
samples, the magnitude of increase in methylation correlated with the intracellular 2HG
levels produced by IDH transfection (Figure 3.1C). To test whether histone lysine
methylation was dysregulated in gliomas with IDH mutation, immunohistochemistry
analysis of patient oligodendroglioma samples was performed for several wellcharacterized histone marks. Compared to tumors with wild-type IDH, there was a
statistically significant increase in the repressive trimethylation of H3K9 (H3K9me3) and
an increasing trend in trimethylation of H3K27 (H3K27me3) in tumors with IDH1
mutation (Figure 3.1D). No statistically significant difference was seen in trimethylation
of H3K4 (H3K4me3), a mark associated with active transcription (data not shown).
These data suggested that IDH mutations might preferentially affect the regulation of
repressive histone methylation marks in vivo.
As IDH mutations were associated with glial tumors of the ‘proneural’ phenotype
(Verhaak et al., 2010), we sought to determine whether the persistence of histone
repressive marks promoted by mutant IDH was sufficient to block the differentiation of
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Figure 3.1: IDH mutations are associated with dysregulation of glial differentiation
and global histone methylation.
(A) Heatmap representation of a two-dimensional hierarchical clustering of genes
identified as differentially expressed between IDH1/2-mutant patient oligodendroglioma
samples and IDH1/2-wild-type samples. Each row represents a gene and each column
represents a specimen. IDH mutational status, tumor grade and recurrence of each sample
are listed. (B) List of top four gene-ontology categories enriched in differentially
expressed genes between IDH1/2-mutant vs. wild-type glioma samples. (C) 293T cells
transfected with empty vector, wild-type or R132H mutant IDH1, or wild-type or R172K
mutant IDH2 were lysed and assessed for expression levels of IDH1, IDH2 and histone
lysine methylation marks by Western blotting with specific antibodies. Lower panel
provides quantification of intracellular 2HG. (D) IHC staining with antibodies against
H3K9me3 and H3K27me3 in IDH1/2 wild-type and IDH1 mutant oligodendroglioma
samples. Image quantification was shown in lower panels.
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non-transformed cells. Upon stimulation with a differentiation cocktail, immortalized
murine 3T3-L1 cells undergo extensive chromatin remodelling, resulting in their
maturation into adipocytes (MacDougald and Lane, 1995). 3T3-L1 cells transduced with
R172K mutant IDH2 produced 2HG whereas cells transduced with either wild-type IDH2
or vector alone did not (Figure 3.2A). All three cell types were then induced to
differentiate into adipocytes. After 7 days of differentiation induction, IDH mutant cells
had visibly reduced lipid droplet accumulation compared to vector and IDH wild-type
cells, as shown by Oil-Red-O staining (Figure 3.2B). To determine whether 2HG was
sufficient to mediate the effect of mutant IDH on cell differentiation, we synthesized cellpermeable 1-octyl-d-2-hydroxyglutarate (octyl-2HG). Treatment of 3T3-L1 cells with
octyl-2HG led to a dose-dependent inhibition of lipid accumulation (Figure 3.2C). Gene
expression analysis showed that despite exposure to a well-standardized differentiation
protocol, IDH mutant cells or cells treated with octyl-2HG exhibited a profound defect in
the expression of transcription factors essential for executing adipogenesis (Cebpa and
Pparg) and an adipocytic lineage-specific gene (Adipoq) (Figures 3.2D and 3.2E),
suggesting that these cells failed to execute adipocyte differentiation.
Cells were harvested for a chromatin immunoprecipitation (ChIP) assay using antibodies
against H3K9me3 and H3K27me3, before or after 4 days of differentiation induction.
Quantitative polymerase chain reaction (PCR) with primers targeting promoters of Cebpa
and Adipoq revealed that at day 4 there was a statistically significant increase in
H3K9me3 and H3K27me3 at promoters of both genes in IDH mutant cells (Figure 3.3A).
These repressive marks also showed a modest but significant increase at gene promoters
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Figure 3.2: Differentiation arrest induced by mutant IDH or 2HG.
(A) 3T3-L1 cells stably expressing empty vector, wild-type, or R172K mutant IDH2 were
lysed and assessed for expression levels of IDH2 or IDH1 by Western blotting. Cells
were also extracted for intracellular metabolites which were then derivatized and
analyzed by GC-MS. The quantification of 2HG signal intensity relative to the
intrasample glutamate signal is shown. (B) Cells were induced to differentiate into
mature adipocytes for 7 days. The accumulation of lipid droplets was assessed by Oil-red
O staining. (C) 3T3-L1 cells were induced to differentiate for 7 days in the absence or
presence of 1 mM or 2 mM octyl-2HG. Oil-red O staining was performed and quantified
by measuring absorbance at 500 nm. (D) Vector, wild-type or R172K mutant IDH2
transduced 3T3-L1 cells were induced to differentiate for 4 days. RNA was extracted.
Relative expression of genes was assessed by RT-qPCR. (E) 3T3-L1 cells were induced
to differentiate for 4 days in the absence or presence of 1 mM or 2 mM octyl-2HG. RNA
was extracted. Relative expression of genes was assessed by RT-qPCR. *, p < 0.05; **, p
< 0.01; n.s., not significant.
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Figure 3.3: Differentiation arrest induced by mutant IDH is associated with
increased global and promoter-specific H3K9 and H3K27 methylation.
(A) Vector, wild-type or R172K mutant IDH2 transduced 3T3-L1 cells were induced to
differentiate. At d0 and d4, ChIP analysis was performed using antibodies against
H3K9me3 and H3K27me3. Immunoprecipitated Cebpa and Adipoq promoter sequences
were analyzed by qPCR and shown as percentage of input. Error bars indicate s.d. from
triplicate wells. (B) 3T3-L1 cells stably expressing empty vector, wild-type, or R172K
mutant IDH2 were induced to differentiate into mature adipocytes for 4 days. DNA was
extracted from cells and bisulfite-converted. Promoter DNA methylation levels were
assessed by MassARRAY (Sequenom). MassARRAY coverage for each promoter was
indicated. Percentage of methylation was shown for triplicate samples from each
condition. (C) Vector, wild-type or R172K mutant IDH2 transduced 3T3-L1 cells were
induced to differentiate for 4 days. At days 0 and 4 (d0 and d4), histones were acidextracted and levels of H3K9me3, H3K9me2 and acetyl-H3 were assessed by Western
blotting with specific antibodies. Total H3 was used as loading control. *, p < 0.05; **, p
< 0.01; n.s., not significant.
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before differentiation induction. In contrast, quantitative assessment of DNA methylation
at promoters of Cebpa and Adipoq by MassARRAY failed to reveal any significant
difference between IDH wild-type and mutant cells (Figure 3.3B). In addition to genespecific changes, we detected a global increase in H3K9 methylation and a reciprocal
decrease in H3 acetylation (Figure 3.3C).
To determine whether IDH mutation was sufficient to induce enhanced repressive histone
methylation in central nervous system (CNS)-derived cells and whether it was associated
with altered neural gene expression, we retrovirally transduced immortalized normal
humanastrocytes (NHAs) with either wild-type or R132H mutant IDH1. Compared to
parental cells, late-passage cells expressing mutant IDH exhibited elevated levels of a
variety of histone methylation marks (Figure 3.4A), and this correlated with an enhanced
expression of the neural marker nestin (Figure 3.4B). Since IDH mutations have been
associated with CpG-island hypermethylation and histone repressive marks can promote
DNA methylation and vice versa, we studied the temporal relationship of histone and
DNA methylation in IDH-expressing astrocytes (Figures 3.4C-3.4E). The first observable
change of the histone marks we examined was H3K9me3. H3K9me3 levels were
significantly elevated by passage 12 after cells were infected with mutant IDH. Changes
in other histone methylation marks were either delayed and of lower magnitude
(H3K27me3 and H3K79me2) or were not observed (H3K4me3). Increases in DNA
methylation were never observed before passage 17 and the difference in DNA
methylation reached statistical significance only at passage 22.
To test whether the IDH1 R132H mutation could interfere with neural differentiation in
the absence of prolonged adaptation in culture, primary neurosphere cultures established
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Figure 3.4: IDH mutation induces histone methylation increase in CNS-derived cells.
(A) Histones from parental NHA cells or cells transduced with wild-type or R132H
mutant IDH were acid-extracted at late (>40) passages. Histone lysine methylation levels
were assessed by Western blotting with specific antibodies. (B) Parental, IDH1 wild-type
and R132H mutant NHA cells at late passages were lysed and assessed for expression
levels of nestin by Western blotting. (C) Histones from NHA cells transduced with wildtype or R132H mutant IDH were acid-extracted at different time points as cells were
passaged in culture. Histone lysine methylation levels were assessed by Western blotting
with specific antibodies. (D) Western blot band intensities of H3K9me3 were quantified
using Image J. (E) Total CpG methylation of IDH1 wild-type and R132H mutant NHA
cells at various passages was measured by FACS using 5-methylcytosine-specific
antibody and shown as normalized mean fluorescence intensity.
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Figure 3.5: IDH mutation can alter cell lineage gene expression.
(A) Primary neurosphere cultures established from the brains of p16/p19-/- mice were
retrovirally transduced with empty vector, wild-type or R132H mutant IDH1. Levels of
protein expression of wild-type IDH1 or mutant IDH1 were analyzed by Western blotting
with specific antibodies. (B) Neurosphere cultures established from the subventricular
zone of brains of p16/p19-/- mice were infected with a retroviral construct containing
IDH1 R132H mutant, wild-type IDH1 or the vector alone and induced to differentiate.
GFAP and β3-tubulin expression levels were assessed by Western blotting. p85 was used
as loading control.
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from the brains of p16/p19−/− mice were infected with a retroviral construct containing
IDH1 R132H mutant, wild-type IDH1 or the vector alone (Figure 3.5A). After infection
the cells were re-plated under conditions that promote astrocyte differentiation and
induced to differentiate further by treatment with retinoic acid without further passaging.
IDH mutant cells failed to induce expression of the astrocytic marker GFAP and
exhibited expression of the neural marker β3-tubulin (Figure 3.5B). When the
differentiation conditions were supplemented with retinoic acid, enhanced expression of
the astrocytic marker GFAP was observed in IDH wild-type and vector cells but GFAP
expression remained repressed in IDH mutant cells.
The enhancement of H3K9 methylation in mutant IDH-expressing cells from multiple
tissues of origin led us to investigate whether this H3K9 methylation might be sufficient
to block the ability of non-transformed cells to execute differentiation. Support for this
hypothesis came with the discovery that KDM4C (also known as JMJD2C), an H3K9specific JHDM, was induced in 3T3-L1 cells during differentiation (Figure 3.6A). An in
vitro histone demethylase assay with recombinant human GST-tagged KDM4C
confirmed that KDM4C effectively removed H3K9me2 and H3K9me3 in the presence of
αKG. Importantly, the demethylation reaction was inhibited by 2HG in a dose-dependent
manner (Figures 3.6B and 3.6C). Given the similarities between 2HG and αKG, the
inhibition of KDM4C by 2HG would be predicted to be competitive. Consistently,
increasing the concentration of αKG in the reaction mixture reversed the inhibition of
H3K9 demethylation by 2HG (Figure 3.6D).
Finally, to test the possibility that H3K9 demethylation is a required component of
adipocyte differentiation, we examined whether blocking the induction of KDM4C was
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sufficient to impair the differentiation of 3T3-L1 cells. Treatment with short interfering
RNA (siRNA) against KDM4C reduced its expression and enhanced H3K9me3 in 3T3L1 cells (Figures 3.7). After differentiation induction, cells treated with KDM4C siRNA
exhibited reduced ability to differentiate into adipocytes (Figures 3.7). Thus the inability
to erase repressive H3K9 methylation can be sufficient to impair the differentiation of
non-transformed cells.
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Figure 3.6: 2HG inhibits H3K9 demethylase KDM4C.
(A) 3T3-L1 cells were induced to differentiate for 3 days. Before (d0) and each day after
differentiation induction, cells were lysed and KDM4C protein levels were assessed by
Western blotting with specific antibody. (B) Bulk histones were incubated with purified
GST-tagged human KDM4C in the reaction mix with 1 mM αKG and increasing
concentrations of D-2HG. Levels of GST-tag, H3K9me3 and H3K9me2 were assessed by
Western blotting with specific antibodies. (C) Bulk histones were incubated with purified
GST-tagged human KDM4C in the reaction mix with 2, 5 or 10 mM D-2HG or L-2HG.
Levels of H3K9me3 were assessed by Western blotting with specific antibody. (D) Bulk
histones were incubated with purified GST-tagged human KDM4C in the reaction mix.
10 mM D-2HG was added to inhibit the demethylation reaction in the presence of
increasing concentrations of αKG. Levels of H3K9me3 were assessed by Western
blotting with specific antibody.
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Figure 3.7: KDM4C is required for cell differentiation.
3T3-L1 cells were transfected with control siRNA or siRNA specific for KDM4C. After
three days, cells were lysed and assessed for expression levels of KDM4C and H3K9me3
by Western blotting with specific antibodies. Cells from the same treatment were induced
to differentiate for 7 days. The accumulation of lipid droplets was assessed by Oil-red O
staining. Wells from a representative experiment from a total of 3 independent
experiments are shown.
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Discussion
Biochemical studies suggest that 2HG is a universal inhibitor of JHDM family members
(Chowdhury et al., 2011; Xu et al., 2011); therefore it was interesting to observe that
H3K9 demethylation seemed to be more sensitive to mutant IDH-induced suppression
than at least some other histone methylation marks. This may be because H3K9
demethylases are more sensitive to inhibition by 2HG in comparison to other JHDM
family members. Alternatively, H3K9 methylation is a histone mark that positively
correlates with DNA methylation and participates in repressive heterochromatin
formation associated with HP1 recruitment. H3K9 methylation is also mutually exclusive
with H3K9 acetylation, a mark that positively correlates with increased gene expression
and the promotion of H3K4 methylation at promoters (Latham and Dent, 2007). The fact
that H3K27me3 can also significantly increase in response to IDH mutation suggests that
there is a potential crosstalk between H3K9 methylation and Trithorax and Polycomb
group proteins that regulate H3K4 and H3K27 methylation, respectively. In addition,
given the delayed kinetics of other alterations in histone marks following introduction of
mutant IDH, some of these changes may result from a mutant IDH-induced block in
differentiation rather than direct inhibition of the relevant demethylases. It should be
noted that KDM4C is not the only H3K9 demethylase and the fact that H3K9 methylation
is increased in mutant IDH-infected fibroblasts prior to the induction of adipocytic
differentiation suggests that 2HG is affecting additional H3K9 demethylases which have
been shown to share a structurally similar binding pocket but can exhibit tissue-and
development-specific variations in their expression (Ng et al., 2007). Future investigation
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of the sensitivity to 2HG inhibition among JHDM family members and/or cellular
feedback mechanisms activated after defective histone demethylation will be needed.
In addition to the data presented here, evidence is mounting for a direct role of histone
methylation in stem cell maintenance, differentiation and tumorigenesis. For example, the
MLL gene, which encodes a H3K4 methyltransferase, is involved in chromosomal
rearrangement in ~80% of infant leukemia and 5-10% of adult AML (Krivtsov and
Armstrong, 2007). KDM3B (also known as JMJD1B) is an H3K9 demethylase which is
located at chromosome 5q31, a region frequently deleted in AML and myelodysplastic
syndrome (Hu et al., 2001). More recently, systematic mutational screens of the coding
genome identified inactivating mutations of KDM6A (H3K27 demethylase, also known
as UTX) in a large array of cancers (van Haaften et al., 2009). A direct role of histone
methylation in stem cell maintenance and differentiation has also been shown. For
example, loss of KMT1E (also known as SETDB1), a H3K9 methyltransferase, resulted
in impaired stem cell renewal (Bilodeau et al., 2009). Recently, KMT1E was found to be
recurrently amplified in melanoma and accelerated melanoma onset after BRAF mutation
(Ceol et al., 2011). The present data suggest that 2HG-producing IDH mutations
represent an additional mechanism to impair the function of histone demethylases and
thus block cellular differentiation.
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Chapter 4
Differentiation blockade, resistance to contact inhibition and
tumorigenesis by mutant IDH involves DNA hypermethylation
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Summary
Frequent mutations of the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and
IDH2 are found in multiple types of cancer. The mutations result in the accumulation of
2HG, a putative “oncometabolite” which is believed to mediate the oncogenic potential
of mutant IDH. However, it is unclear whether mutant IDH is sufficient for tumorigenesis
in vivo and the role of 2HG in the transformation process. Furthermore, despite strong
evidence linking IDH mutation to DNA and histone hypermethylation, it remains to be
shown that epigenetic misregulation contribute to the malignant phenotype caused by
mutant IDH. Here we report that in a non-transformed murine mesenchymal multipotent
cell line, expression of an IDH mutant impaired mesenchymal differentiation, induced
loss of contact inhibition and generated highly mitotic mesenchymal tumors in xenograft
study. DNA methylation profiling at base-resolution revealed a profound genome-wide
CpG hypermethylation in IDH mutant cells which is enriched for genes involved in cellcell contact. Our data suggest that epigenetic abnormality and the resultant aberrant gene
expression represent a critical step in the initiation and progression of tumors with IDH
mutation.

50

Introduction
Since the original observation by the German biochemist Otto Warburg that cancer cells
utilize glucose in a fundamentally different way from normal cells (Warburg, 1956), the
recent resurgence in cancer metabolism research led to the increasing appreciation that
metabolic reprogramming is a hallmark of cancer (Vander Heiden et al., 2009; Ward and
Thompson, 2012). However, it remains controversial whether metabolism rewiring
observed in cancer plays a significant role in driving cancer development. A strong
argument in support of this hypothesis is the recent identification of cancer-associated
germline and somatic alterations of genes encoding for metabolic enzymes (Mullarky et
al., 2011; Oermann et al., 2012), including prevalent mutations in isocitrate
dehydrogenase 1 (IDH1) and IDH2.
Cytosolic IDH1 and mitochondrial IDH2 are NADP+ -dependent enzymes that
metabolize isocitrate to αKG. Frequent somatic mutations of IDH1 and IDH2 were
identified in intermediate-grade gliomas (Yan et al., 2009), adult de novo acute myeloid
leukemias (AMLs) (Mardis et al., 2009; Ward et al., 2010) and subsets of
chondrosarcomas, lymphomas and cholangiocarcinomas (Amary et al., 2011; Borger et
al., 2012; Cairns et al., 2012). The fact that mutations observed in IDH1 and IDH2 are
always heterozygous point mutations affecting only a few residues suggests that they are
unlikely loss of function. Indeed, metabolomic and biochemical analysis revealed that
mutant IDHs gain a neomorphic activity of producing 2-hydroxyglutarate (2HG) from
αKG (Dang et al., 2009; Ward et al., 2010). 2HG is normally present at very low levels in
cells and as high as 100-fold increase in 2HG was observed in patient samples with IDH
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mutation. It is believed that IDH mutations promote tumorigenesis through accumulating
the putative “oncometabolite” 2HG.
At the molecular level, mounting evidence implicate a link between IDH mutation and
epigenetic dysregulation, particularly DNA hypermethylation. In multiple malignancies,
IDH mutations are tightly associated with a CpG island methylator phenotype (CIMP) in
patient samples (Figueroa et al., 2010a; Noushmehr et al., 2010; Pansuriya et al., 2011;
Wang et al., 2012), and expression of an IDH mutant in cell lines is sufficient to cause
DNA hypermethylation (Figueroa et al., 2010a; Turcan et al., 2012). Mechanistically,
mutant IDH was shown to impair activities of αKG-dependent chromatin modifying
enzymes by producing 2HG as a competitive inhibitor. These include TET family
enzymes which converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), a
novel epigenetic mark potentially involved in DNA demethylation (Figueroa et al.,
2010a); as well as Jumonji-C histone demethylases (Chowdhury et al., 2011; Lu et al.,
2012). Importantly, genetic profiling of AML samples revealed a mutual exclusivity
between IDH mutations and TET2 loss of function mutations, providing strong genetic
evidence that IDH mutation may support tumorigenesis through modulating αKGdependent chromatin modifier and the resultant hypermethylation of DNA and histone.
Despite the advance in understanding the molecular mechanism, it is yet to be shown
whether mutant IDH is sufficient for tumorigenesis. Here we report that in a nontransformed murine mesenchymal progenitor cell line, IDH mutation leads to impaired
mesenchymal lineage differentiation and loss of contact inhibition. Importantly, mutant
IDH cells form highly mitotic tumors in mouse xenograft study. DNA methylation
sequencing at base-pair resolution showed that IDH mutant cells display genome-wide
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DNA hypermethylation, including key genes involved in cell adhesion. Collectively our
data suggest that increased DNA methylation represents a critical step in the
transformation by mutant IDH.
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Results
IDH mutation inhibits mesenchymal lineage differentiation
We have previously reported that IDH mutation could block the adipocyte differentiation
from non-transformed mouse 3T3-L1 fibroblasts (Lu et al., 2012). To determine the
generality of these findings, we retrovirally transduced C3H10T1/2 (10T) cells with
vectors containing either wild-type or R172K mutant IDH2. 10T cells were originally
isolated from C3H mouse embryo. They were sensitive to confluence-induced
proliferation arrest and showed no tumorigenicity in xenograft study (Reznikoff et al.,
1973). Subsequently, 10T cells were demonstrated to be multipotent with the ability to
differentiate into several mesenchymal lineages, including adipocytes, myoblasts and
chondrocytes (Taylor and Jones, 1979). Notably, IDH mutations are found at high
frequencies in chondrocytic sarcomas (Amary et al., 2011). 10T cells expressing R172K
mutant IDH2 but not empty vector or wild-type (WT) IDH2 showed significant increase
in 2HG levels (Figures 4.1A and 4.1B).
Consistent with previous findings, upon adipogenesis induction, IDH2 mutant cells
showed a profound impairment in adipocyte differentiation with a lack of lipid droplets
accumulation and absence of adipocyte-specific gene expression (Adipoq and Fabp4)
compared to vector and WT IDH2 cells (Figure 4.1C). Similarly, when cells were
subjected to conditions that promote chondrogenesis, morphological conversion from
fibroblast-like to rounded shapes resembling mature chondrocytes and expression of
chondrocyte-specific markers Acan and Col2a1 were only observed in vector and WT
IDH2 cells but not IDH2 mutant cells (Figure 4.1D). Furthermore, while vector and WT
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Figure 4.1: IDH mutation inhibits mesenchymal lineage differentiation.
(A) 10T cells were retrovirally transduced with empty vector or vectors containing either
WT or R172K mutant IDH2. After puromycin selection, levels of IDH2 protein were
assessed by Western blot. (B) Levels of 2HG measured by GC-MS in 10T cells
expressing vector, WT or mutant IDH2. (C) Vector, WT or mutant IDH2 cells were
treated with adipogenesis cocktail. Microscopic images of cell morphology were
recorded 7 days after differentiation. mRNA expression of Adipoq and Fabp4 was
measured by Q-RTPCR. (D) Vector, WT or mutant IDH2 cells were treated with
chondrogenesis cocktail. Microscopic images of cell morphology were recorded 10 days
after differentiation. mRNA expression of Acan and Col2a1 was measured by Q-RTPCR.
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IDH2 cells became growth arrested after the induction of adipocyte or chondrocyte
differentiation, IDH2 mutant cells continued to proliferate (Figure 4.2A) and maintained
high levels of cyclin D1 (Figure 4.2B). Taken together these data suggest that
differentiation blockade by IDH mutation is a common feature shared by multiple
mesenchymal lineages.
IDH mutant cells escape contact inhibition and generate tumors in vivo
The differentiation experiments described above require cells to be seeded at confluence
before induction. Therefore the observations that IDH mutant cells were able to continue
proliferation at post-confluence prompted us to determine whether these cells have
become insensitive to contact inhibition. When cultured in normal growth medium,
vector, WT IDH2 or IDH2 mutant cells showed no difference in proliferation rate at
sparse (day 0 – day 2, Figure 4.3A). However, while vector and WT IDH2 cells stopped
proliferation after reaching confluence (day 4 – day 6), the accumulation of IDH2 mutant
cells continued even after confluency was achieved. Cell cycle analysis showed that
IDH2 mutant cells had a higher percentage of cell population in G2 and S phase at postconfluence (Figure 4.3B). Moreover, the induction of cell cycle inhibitor p27 and the
decrease in levels of cyclin D1 after contact inhibition were less pronounced in IDH2
mutant cells (Figure 4.3C).
IDH2 mutant cells underwent cell cycle arrest normally after serum deprivation (Figure
4.3D), suggesting that their escape from contact inhibition is unlikely due to defects in
cell cycle regulation. The cadherins are critical components of cell-cell adhesion and
have been proposed to be the main upstream mediator of contact inhibition
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Figure 4.2: Differentiation blockade led to sustained proliferation of IDH mutant
cells.
(A) 10T vector, WT or mutant IDH2 cells were treated with adipogenesis or
chondrogenesis cocktail. Cell numbers were counted at day 0, 3, 6 after differentiation
induction. (B) 10T vector, WT or mutant IDH2 cells were treated with adipogenesis or
chondrogenesis cocktail. Six days after differentiation, cells were lysed and protein levels
of cyclin D1 and p27 were measured by Western blot.
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Figure 4.3: IDH mutant cells escape contact inhibition.
(A) 10T vector, WT or mutant IDH2 cells were cultured in normal growth medium and
cell numbers were counted at day 0, 2, 4 and 6. Cells reached confluence at day 4. (B)
FACS cell cycle analysis of vector, WT or mutant IDH2 cells at post-confluence day 2.
(C) Vector, WT or mutant IDH2 cells were lysed at sparse, at confluence or 2 days postconfluence. Protein levels of cyclin D1 and p27 were measured by Western blot. (D)
FACS cell cycle analysis of vector, WT or mutant IDH2 cells at sparse in growth medium
with 10% or 0.1% fetal calf serum. (E) Vector, WT or mutant IDH2 cells were lysed at
sparse or 2 days post-confluence. Levels of N-cadherin protein expression were measured
by Western blot and mRNA expression was measured by Q-RTPCR.
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(Gumbiner, 2005). We found that unlike vector and WT IDH2 cells, IDH2 mutant cells
failed to upregulate N-cadherin protein and mRNA expression after contact inhibition
(Figures 4.3E), suggesting that the post-confluence growth of these cells might be the
result of inability to sense cell-cell contact at surface membrane.
Since loss of contact inhibition is a classical feature of tumor cells and often indicates
transformation, we next tested whether 10T cells with IDH mutation generate tumors in
vivo. IDH2 mutant cells formed palpable tumors after 20 days of subcutaneous injection
and continued to grow up to 1000 m3, while vector and WT IDH2 cells showed no
tumorigenecity over the course of study (Figure 4.4A). Immunohistochemistry staining
revealed that IDH2 mutant tumors were highly mitotic with high Ki67 index (Figure
4.4B). Consistent with cell culture study, these tumors also had high levels of cyclin D1
and low p27 expression.
IDH mutation induces DNA hypermethylation
We next sought to determine the mechanism of tumorigenesis by IDH mutation. Previous
reports implicate a role of 2HG in inhibiting αKG-dependent chromatin modifying
enzymes including TET2 and jumonji-C histone demethylases. These enzymes belong to
the superfamily of αKG-dependent dioxgenases, which consist of ~100 members
covering diverse biological functions. Among them, 2HG has been proposed to affect
activities of prolyl hydroxylases 2 (PHD2) which hydroxylases HIF1α for degradation
(Koivunen et al., 2012; Zhao et al., 2009). Moreover, in a knock-in IDH1 mutant mouse
model, 2HG was shown to disrupt collagen processing and cause endoplasmic reticulum
(ER) stress response by inhibiting collagen prolyl-hydroxylation (Sasaki et al., 2012a).
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Figure 4.4: IDH mutant cells generate tumors in vivo.
(A) 10 millions of 10T vector, WT or mutant IDH2 cells at passage 20 were
subcutaneously injected into nude mice. Tumor implantation and growth were monitored
and measured. Images are shown for mice injected with WT cells (left) or mutant cells
(right). (B) IHC analysis was performed on mutant IDH2 tumors and representative
images are shown for H&E, Ki67, cyclin D1 and p27.
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We found that soluble fraction of collagen IV seemed to increase in IDH2 mutant cells
with a faster migration pattern on SDS gel, suggesting a possible reduced hydroxylation
and delayed processing of collagen IV (Figure 4.5A). In addition, we observed a
decreased expression of collagen I. However, coating cell culture plates with collagen
did not blunt the post-confluence proliferation of mutant IDH2 cells (Figure 4.5B). There
was no difference in the levels of ER stress response between IDH2 mutant and WT cells
either (Figure 4.5C), suggesting that the mild defect in collagen secretion is unlikely to
account for the tumorigenecity of IDH2 mutant cells. Finally, the HIF1α accumulation
under hypoxia seemed to be unaffected by IDH2 mutation (Figure 4.5D).
When we extracted DNAs from cells cultured at sparse and subjected them to extended
reduced representation bisulfite sequencing (ERRBS) to obtain base-resolution DNA
methylation profiles (Akalin et al., 2012), IDH2 mutant cells showed a genome-wide
distribution of differentially methylated CpG sites with a profound hypermethylation
across all chromosomes (Figure 4.6A). Among the 2,400 genes with differentially
methylated cytosines at the promoters, we observed a predominance in hypermethylation
which was highly statistical significant (78.1 % being hypermethylated, p-value < 0.0001
by Chi-square test). In contrast, significantly less differentially methylated cytosines were
observed between WT IDH2 and vector cells with even distribution of hypermethylated
and hypomethylated sites (Figure 4.6B). Pathway enrichment analysis of the
hypermethylated sites between IDH2 mutant and WT cells revealed genes involved in
cell adhesion and WNT signaling pathways which are implicated in the response to cellcell contact (Figure 4.6C). Finally, we also found increased methylation at several histone
marks such as H3K9me3, H3K9me2 and H3K4me3 in IDH2 mutant cells, which could
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Figure 4.5: Collagen processing and HIF signaling in IDH mutant cells.
(A) 10T vector, WT or mutant IDH2 cells were lysed and protein levels of collagen I and
collagen IV in the solution fraction were measured by Western blot. (B) 10T vector, WT
or mutant IDH2 cells were seeded on normal cell culture plates or plates coated with
collagen and cell numbers were counted at day 0, 2, 4 and 6. Cells reached confluence at
day 4. (C) Vector, WT or mutant IDH2 cells and 10T parental cells treated with ER stress
inducer tunicamycin were lysed and protein levels of Bip and CHOP were measured by
Western blot. (D) Vector, WT or mutant IDH2 cells were lysed under normoxia or after 6
hour under 0.5% hypoxia. Protein levels of HIF1α were measured by Western blot.
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reinforce with DNA methylation to modulate gene expression and facilitate the
transformation by mutant IDH (Figure 4.6D).

63

Figure 4.6: IDH mutation induces DNA hypermethylation.
(A) and (B) Stacking barplots showing percentage of hyper and hypomethylated
differentially methylated cytosines out of all covered CpGs for each chromosome
comparing IDH mutant vs. WT and IDH WT vs. vector. Green represents proportion of
hypomethylated cytosines and magenta represents hypermethylated ones. Only CpGs
with q-value<0.01 and methylation difference of at least 25% are shown. (C) Pathway
enrichment analysis of hypermethylated genes in mutant IDH2 cells. (D) Histones were
acid-extracted from vector, WT or mutant IDH2 cells at sparse. Levels of histone
methylation were measured by Western blot.
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Discussion
The research on IDH mutations has been hampered by a lack of robust model system. We
previously found that IDH mutation blocked adipocyte differentiation from mouse
fibroblasts (Lu et al., 2012). This finding has been extended to the hematopoietic system
with the observations that mutant IDH and 2HG could impair EPO-induced erythrocyte
differentiation in an erythroleukemic cell line (Losman et al., 2013) and that
hematopoietic-specific conditional knock-in IDH1 R132H mutant mice had an expansion
in early haematopoietic progenitor/stem cell population (Sasaki et al., 2012b).
Nevertheless, none of the previous studies reported in vivo tumorigenecity of mutant IDH,
which led to the hypothesis that IDH mutation is insufficient for tumorigenesis. We
report here that using a non-transformed murine mesenchymal multipotent cell line,
expression of an IDH mutant not only arrested cells from differentiating into adipocytic
and chondrocytic lineages, but also resulted in loss of contact inhibition and tumor
formation in vivo. It should be noted that while differentiation impairment was observed
shortly after IDH2 mutant expression, contact inhibition required >15 passages of cells in
culture, suggesting that the later phenotype may be the result of gradual epigenetic
silencing of key genes involved in cell-cell contact.
The common feature shared by all IDH mutations is the production of 2HG. Although the
truncated reverse reaction by mutant IDH also consumes NADPH, its impact on total
cellular NADPH pool is likely minimal due to a much slower rate compared to the
forward reaction by WT IDH(Dang et al., 2009). Importantly, exogenous 2HG could
recapitulate mutant IDH’s effect on blocking cell differentiation (Losman et al., 2013; Lu
et al., 2012). These data have led to the belief that 2HG is the major mediator of mutant
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IDH’s oncogenic potential. Despite a strong link between 2HG and αKG-dependent
chromatin modifying enzymes, 2HG is a competitive inhibitor for several additional
αKG-dependent enzymes in vitro (Xu et al., 2011) and in certain context, its impact on
enzymes such as prolyl hydroxylases could lead to important biological consequences
(Koivunen et al., 2012; Sasaki et al., 2012a). We therefore tested mutant IDH’s effect on
collagen processing and HIF signaling in our system. The data suggest that HIF signaling
was unaffected. Although a mild defect in collagen processing was observed, it did not
significantly contribute to the loss of contact inhibition by mutant IDH2. In contrast,
DNA methylation profiling at base resolution identified a profound chromosome-wide
increase in hypermethylated cytosines in IDH2 mutant cells, presumably due to the
inhibition of TET family enzymes. There was also global elevation in histone
methylation most likely resulting from 2HG’s inhibition of Jumonji-C histone
demethylases. Importantly, gene enrichment analysis identified groups of genes involved
in contact inhibition that were over-represented in hypermethylated loci. Collectively our
findings suggest that chronic inhibition of TET and Jumonji-C histone demethylase may
lead to DNA hypermethylation and permanent silencing of genes that are required for
proper response to contact inhibition.
There is a strong interest in developing inhibitors that specifically abrogate mutant IDH’s
ability to produce 2HG. It was shown that 2HG’s effect on differentiation arrest could be
reversed with delayed kinetics (Losman et al., 2013), suggesting that the epigenetic
abnormality is potentially correctable. It remains to be tested, using our model system,
whether 2HG is required for tumor initiation and/or maintenance in vivo. Given 2HG’s
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remarkable impact on epigenome, it would also be interesting to test whether compounds
targeting chromatin modifiers are selectively toxic to tumors with IDH mutation.
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Chapter 5
Discussion and Conclusion

Parts of this chapter have previously been published in: Lu C, Thompson CB. Metabolic
regulation of epigenetics. Cell Metab 2012 16:9-17.
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The epigenetic basis for the oncogenic potential of 2HG-producing IDH mutation
The work presented in this thesis is based on the initial hypothesis that perturbation of an
important metabolite αKG’s homeostasis can be sensed and responded by cells at the
chromatin level. I sought to address the hypothesis by studying the consequence of
accumulated 2HG, an αKG structural analogue produced by cancer-associated IDH
mutations, on the cellular epigenome. Since IDH mutations are highly prevalent in
multiple types of malignancies and are likely to be driver mutations, the model could also
help understand how the putative “oncometabolite” 2HG initiates and/or promotes
tumorigenesis. I provided several lines of evidence in this thesis supporting the
conclusion that not only could 2HG lead to misregulated chromatin modification and
remodeling, the resultant epigenetic abnormality also forms the basis for altered cell
behavior that are important for tumorigenecity by IDH mutation.
Structural analysis of Jumonji-C histone demethylases reveals that the demethylation
reaction requires the coordination of Fe (II) by oxygen atoms in the keto carboxyl end of
αKG (Ng et al., 2007). Therefore it is plausible that substitution of one oxygen atom with
a hydroxyl group on 2HG may interfere with the reaction efficiency. We and others
showed that in vitro 2HG is a competitive inhibitor of histone demethylases and TET
family 5-methylcytosine hydroxylases (Chowdhury et al., 2011; Lu et al., 2012; Xu et al.,
2011). The effective inhibition requires a 2HG:αKG ratio of at least 5:1, suggesting that
2HG is a weak antagonist of these enzymes. However in tumors with IDH mutations,
2HG can accumulate up to 10-50 mM (Dang et al., 2009). Since intracellular
concentration of αKG is estimated to be ~1 mM, the amount of 2HG present is sufficient
to impair the activity of αKG-dependent chromatin modifying enzymes. In agreement, we
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found that ectopic expression of mutant IDH led to remarkable increases in histone and
DNA methylation (Figueroa et al., 2010a; Lu et al., 2012). Of note, while transient
transfection of mutant IDH in 293T cells enhanced methylation of all histone marks
examined, stable expression of mutant IDH over time only resulted in accumulation of
specific repressive histone methylation marks such as H3K9me3 and H3K27me3. This
could be due to the amount of 2HG produced by different transfection methods and the
sensitivity of different Jumonji-C histone demethylases to 2HG inhibition. It could also
be explained by the reinforcement between DNA methylation and repressive histone
methylation marks. Furthermore, in most cell types tested, the increase in DNA and
histone methylation occurred in a passage-dependent manner and could take as long as
10-20 passages. This correlated with the passage-dependent phenotypes induced by
mutant IDH reported by us and others (Koivunen et al., 2012; Lu et al., 2012); and as
discussed in the following it may provide important insights into the mechanism of
hypermethylation establishment.
Multiple independent studies have now demonstrated that differentiation blockade is a
hallmark of cells with IDH mutation (Figueroa et al., 2010a; Losman et al., 2013; Lu et
al., 2012). This is in agreement with the critical role of epigenetic remodeling in cell
lineage specification, as well as the fact that most malignancies involving IDH mutations
are characterized by the accumulation of immature cells. Importantly, the differentiation
blockade could be phenocopied by exogenous 2HG and depletion of 2HG-inhibitable
chromatin modifiers such as TET2 and KDM4C, strongly suggesting that defective
chromatin demethylation underlies the inability to execute differentiation. This is further
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supported by the findings that key genes required for differentiation but not expressed in
IDH mutant cells showed increased levels of repressive H3K9me3 and H3K27me3.
In addition, for the first time we showed that in C3H10T1/2 cells expression of an IDH
mutant could lead to tumor formation in vivo. Base-resolution DNA methylation profiling
revealed a genome-wide CpG hypermethylation which was enriched for genes involved
in response to cell-cell contact. Collectively the data presented in this thesis implicate that
inhibition of histone and DNA demethylation by 2HG and the resultant changes in gene
expression are crucial contributors to the malignant phenotypes induced by mutant IDH.
Since chromatin modifications are potentially reversible, it remains to be explored
whether modulating chromatin modifying enzymes such as DNA and histone
methyltransferases could rescue the phenotypic consequences of IDH mutation.
The present data are supported by findings from patient sample studies. In most cancers
involving IDH mutations, the mutations are tightly associated with a CpG island
methylator phenotype (CIMP) in patient samples (Figueroa et al., 2010a; Noushmehr et
al., 2010; Pansuriya et al., 2011; Wang et al., 2012). Moreover, genetic profiling of AML
samples revealed that loss of function mutations of TET2 were mutually exclusive with
IDH mutations (Figueroa et al., 2010a). In pediatric and young adult gliomas, genes
encoding histone variants H3.3 (H3F3A) and H3.1 (HIST1H3B) were found to be
somatically mutated at specific residues including K27 which appeared to be mutually
exclusive with IDH mutations (Schwartzentruber et al., 2012; Wu et al., 2012). These
genetic and epigenetic evidence strongly argue that IDH mutations can be grouped with
other chromatin mutations and together they constitute disease subgroups characterized
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by epigenetic abnormality. Further sequencing efforts in other types of cancer involving
IDH mutation are required to generalize these findings.
Mechanisms for establishment of hypermethylation
Recently the genome-wide occupancy of Tet1 was mapped by several groups (Wu and
Zhang, 2011). Results showed that Tet1 binds with a high preference for transcription
start sites. Moreover, it was found that Tet1 mainly associates with promoters of high
CpG content. In progenitor cells, promoters with high CpG content are largely DNA
hypomethylated and a significant portion of these promoters are marked by H3K4me3
and H3K27me3. They are enriched for genes involved in regulating differentiation and
development. These findings suggest that an important function of Tet1 is to maintain
these CpG islands free of methylation by hydroxylating and removing accidental
methylation by DNMTs. Since genes showing DNA hypermethylation in cancer tend to
be differentiation-related and are marked by H3K4me3 and H3K27me3 in stem cells
(Ohm et al., 2007; Widschwendter et al., 2007), poisoning TET’s function as a guardian
of DNA methylation fidelity may be a potential mechanism to establish DNA
hypermethylation in cancer (Williams et al., 2012).
These observations are consistent with the present data and I propose that during
differentiation of progenitor cells, Jumonji-C histone demethylase inhibition by the
oncometabolite 2HG causes defective histone demethylation and blocks the accessibility
of differentiation-related genes. In addition, the inhibition of TET and possibly histone
demethylases by 2HG in the long term leads to progressive DNA hypermethylation and
permanently “locks” these genes in a silent state. The resulting differentiation arrest may
facilitate cancer development through accumulation of undifferentiated cells capable of
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self-renewal (Figure 5.1). Future analysis of DNA and histone methylation as well as the
genome-wide distribution of jumonji-C histone demethylase /TET bindings will be
required to test this hypothesis.
Beyond IDH mutation: crosstalk between metabolism and epigenetics in cancer
The analyses of cancer-associated IDH mutations highlight the dynamics and importance
of the interaction between metabolism and epigenetics. As metabolic abnormalities in
cancer continue to be uncovered, studies by others have demonstrated additional
metabolic perturbations that affect chromatin structure.
Germline mutations in FH and SDH and demethylation of histones and DNA
Germline mutations in the SDHD gene were initially discovered in hereditary
paraganglioma through linkage-analysis (Baysal et al., 2000). SDHD gene encodes for a
protein that is a part of the mitochondrial succinate dehydrogenase complex (SDH, as
known as complex II of the mitochondrial respiratory chain) that generates fumarate from
succinate. The mutations were predicted to be loss-of-function. Subsequent sequencing
efforts revealed germline mutations of other subunits of the complex II such as succinate
dehydrogenase subunit B (SDHB), C (SDHC) and SDH5 in the hereditary
paraganglioma and the closely associated phaeochromocytomas (Astuti et al., 2001; Hao
et al., 2009; Niemann and Muller, 2000). Mutations in fumarate hydratase (FH, also
known as fumarase) were identified as the gene causing hereditary leiomyomatosis and
renal-cell cancer syndrome (HLRCC) (Tomlinson et al., 2002). Similar to SDH mutations,
mutations in FH are predicted to be loss-of-function. Biochemically, FH catalyzes the
enzymatic reaction following SDH, converting fumarate to malate.
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Figure 5.1: Model for 2HG’s involvement in epigenetic regulation and cell
differentiation.
When progenitor cells differentiate, JHDM removes repressive histone methylation
marks (H3K9me3 and H3K27me3) and activates the expression of differentiation-related
genes. In addition, TET acts as a failsafe mechanism to protect promoters from aberrant
DNA methylation. 2HG produced by mutant IDH inhibits JHDM and TET, which leads
to histone and DNA hypermethylation and permanently “locks” differentiation-related
genes in a silent state. This results in a differentiation arrest and expansion of progenitor
cells, thus facilitating tumor development.
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Accumulation of fumarate and succinate as the result of SDH and FH mutations has been
proposed to affect HIF signaling as well as the succination of proteins involved in
antioxidant response (Adam et al., 2011; Isaacs et al., 2005; Selak et al., 2005). Given
that structurally both fumarate and succinate are similar to αKG and 2HG, one would
expect that SDH and FH mutations may also affect αKG-dependent chromatin modifying
enzymes. Indeed, it was shown that in vitro and in cells fumarate and succinate can
broadly inhibit αKG-dependent Jumonji-C histone demethylases and TET family
enzymes (Xiao et al., 2012). The functional consequences of these inhibitions remain
unexplored especially in relation to HIF signaling, since unlike cancers with IDH
mutations, paraganglioma, phaeochromocytomas and renal-cell cancers typically exhibit
extensive angiogenesis and vascularization, suggesting the activation of the HIF pathway.
Methionine metabolism and methylation
DNA methyltransferase (DNMTs) and histone methyltransfersase (HMTs) add methyl
groups to DNA or lysine/arginine residues of histones, respectively. Although structurally
diverse and possessing high substrate specificities, DNMTs and HMTs share a similar
reaction mechanism: transferring a methyl group from S-adenosyl methionine (SAM) to
the substrate with the formation of the by-product S-adenosyl homocysteine (SAH).
Since SAH is a very potent inhibitor of DNMTs and HMTs, the key metabolic
determinant of methyltransferase reactions is the ratio between SAM and SAH and rate
of SAH clearance which both depend on the supply of methyl group by various donors.
A recent report identified overexpression of nicotinamide N-methyltransferase (NNMT)
in a variety of human cancers (Ulanovskaya et al., 2013). NNMT also converts SAM to
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SAH, but transfer the methyl group to 1-methylnicotinamide instead of protein or DNA.
It was shown that overexpression of NNMT consumes the methyl unit pool in cells and
as a result decreases the reaction efficiency of HMT and leads to histone
hypomethylation.
Interestingly, mouse embryonic stem cells are highly dependent on extracellular levels of
threonine (Wang et al., 2009). It was recently shown that threonine’s importance was due
to the supply of most methyl units used for histone methylation by its catabolism (ShyhChang et al., 2013). Cells deprived of theronine showed dramatic decrease in H3K4me3.
The catabolic pathway for threonine is absent in human. For proliferating cells in human
the most likely source of methyl units comes from serine/glycine catabolism. Intriguingly,
the key enzyme in serine metabolism pathway, phosphoglycerate dehydrogenase
(PHGDH), was found to be amplified in melanoma and breast cancer (Locasale et al.,
2011; Possemato et al., 2011). It is yet to be shown whether PHGDH amplification could
potentially modulate the cellular methylome and the epigenetic state.
Concluding remarks
The present data demonstrate that the disturbance of αKG homeostasis through IDH
mutation led to altered cellular response to environment trigger, implying that proper
balance of intracellular metabolite levels is a prerequisite for the precise execution of cell
fate specification. Therefore it appears that a “metabolic checkpoint” exists for cells to
determine the nutrient availability in the microenvironment before engaging in fate
decision process. Furthermore, covalent modifications of histone tails and DNA such as
methylation are likely mechanisms to sense and memorize the metabolic state of the cell.
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As many complex diseases such as cancer and type II diabetes display abnormalities of
cellular metabolism and epigenome, it will be critical to understand how cells coordinate
signal transduction and metabolic flux to control chromatin remodeling and gene
expression.
Research on metabolism and epigenetics are progressing at an unprecedented pace and
more exciting discoveries are anticipated to arrive over the near future. Yet technological
challenges are present that must be overcome to unravel the mystery at the next level. As
most metabolites are not diffusible between mitochondria and cytosol/nucleus, accurate
determination of the cytoplasmic pool size is critical to understand their effects on
epigenetic signaling. Although attempts have been made, so far the technology to reliably
measure metabolite concentrations in different cellular compartments is lacking. Even
within the same compartment, local concentration of the metabolite may vary, as
substrate channeling is a common event in cellular metabolism (Huang et al., 2001). This
is relevant, as metabolic enzymes are often present in transcriptional complexes, and thus
could provide a local supply of substrates/co-factors to the complexes in which they
localize. For example, methionine adenosyltransferase IIα (MATIIα), which generates
SAM, was present in chromatin-associated complexes and thought to provide local
substrate for methyltransferases reactions (Katoh et al., 2011). Alternatively metabolic
enzymes may function in these complexes independently of their metabolic activity
(Tristan et al., 2011; Yang et al., 2011). Finally, system biology approaches will become
increasingly important to fully grasp the complexity of the connections between
metabolism and chromatin dynamics. A deeper understanding of these connections may
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help shed light on our understanding of the etiology of a variety of complex diseases
(Katada et al., 2012; Sahar and Sassone-Corsi, 2012).
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Appendix
Materials and Methods

Statistical Analysis: Statistical analysis of demographic factors, disease characteristics,
and mutational frequencies was performed using Fisher’s exact test and Chi-square tests
for categorical variables and t-tests and Mann-Whitney U test for continuous variables.
Statistical analysis for other experiments was performed using Student’s t-test (two
sample equal variance; two-tailed distribution).
Plasmid construction: The cDNA clone of human IDH1 (BC012846.1) was purchased
from ATCC in pCMV-Sport6, and human IDH2 (BC009244) was purchased from
Invitrogen in pOTB7. Standard site-directed mutagenesis techniques were used to
generate IDH1 R132H by introducing a g395a base pair change in the IDH1 open reading
frame (ORF). IDH2 R172K was made by introducing a g515a change in the IDH2 ORF,
while IDH2 R140Q was made with a g419a alteration. Wild-type and mutant sequences
were then subcloned into LPC vector or MIGR1 vector. TET2 cDNA was synthesized
and subcloned into pCMV6-ENTRY (Origene) with a C-terminal FLAG tag and myc tag.
All sequences were confirmed by direct sequencing before expression in 293T cells and
retrovirus generation.
Cell culture, transfection/transduction, and generation of stable cell lines: 293T,
NHA cells immortalized by E6/E7/hTERT (kindly provided by Russ Pieper/UCSF),
C3H10T1/2 and 3T3-L1 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) with 10% fetal bovine serum (FBS, CellGro). 32D cells were
cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum
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and 3 ng/ml recombinant IL-3 (BD Biosciences, 554579). For expression of TET2 cDNA,
TET2 shRNAs, and wild-type and mutant IDH1/2 in 293T cells, transfection was
performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. For generation of IDH2 retrovirus, TET2 shRNA retrovirus and transduction
of 32D and mouse primary bone marrow cells, supernatant from 293T cells transfected
with pCL-Eco helper virus and plasmids was collected after 72 h, filtered and applied to
cells overnight. For generating 32D cell lines with stable expression of wild-type or
mutant IDH2, cells were grown in 2.5 µg/ml puromycin for 7 days following LPC
retroviral transduction. Pooled populations of puromycin-resistant cells were obtained,
and then continuously cultured in puromycin.
For generation of IDH2 retrovirus and transduction of 3T3-L1 and 10T1/2 cells,
supernatant from 293T cells transfected with pCL-Eco helper virus and plasmids was
collected after 72 h, filtered and applied to cells overnight. For generating 3T3-L1 and
10T1/2 cell lines with stable expression of wild-type or mutant IDH2, cells were grown
in 2.5 µg/ml puromycin for 7 days following retroviral transduction. Pooled populations
of puromycin-resistant cells were obtained, and then continuously cultured in puromycin.
For generation of IDH1 retrovirus and transduction of NHA cells, GP2-293 cells
(Clontech, 631458) were calcium phosphate transfected with equal amounts of pVSV-G
(Clontech, 631512) and plasmids. Virus was harvested at day 2 and day 3 after
transfection and placed on logarithmically growing cells. After infection, cells were
placed in 800 µg/mL G418 (Invitrogen) to generate stable cell lines.
For siRNA knockdown of KDM4C, transfections were performed with Lipofectamine
RNAiMAX (Invitrogen), using siRNAs targeting KDM4C (#1: sense 5’80

GCUUGAAUCUCCCAAGAUAtt-3’ antisense 5’-UAUCUUGGGAGAUUCAAGCtt-3’;
#2: sense 5’-CAAAGUAUCUUGGAUCAAAtt-3’ antisense 5’UUUGAUCCAAGAUACUUUGcc-3’; #3: sense 5’GAGGAGUUUCGGGAGUUCAACAAAU-3’ antisense 5’AUUUGUUGAACUCCCGAAACUCCUC-3’) or a non-targeting control (Dharmacon,
#D-001810-01-20) at a concentration of 40 nM.
Tet2 shRNA experiments: Oligonucleotide sequences targeting murine Tet2
(NM_001040400) were selected on the basis of BIOPREDsi algorithms and are available
upon request. Individual shRNAs for validation were synthesized as 97 bp oligos (Sigma
Genosys), PCR-amplified, cloned into LMS (MSCV-based vectors encoding GFP), and
verified by sequencing. Tet2 KD was verified by qRT-PCR using SYBR green
quantification in an ABI 7500 sequence detection system. The following primers for Tet2
were used to verify KD: Forward 5’-CAAAGATGAAGCTCCTTATTATACC-3’;
Reverse 5’-ACATCCCTGAGAGCTCTTGC-3’.
Immunofluorescence staining and quantification: Cells were seeded in Lab-tech II 4wells chamberslides (Electron Microscopy Sciences) after transfection. After wash with
PBS, cells were fixed with paraformaldehyde (3%) for 10 min at room temperature and
permeabilized with 0.2% Triton X-100 for 20 min. Cells were then treated with 2N HCL
for 30 min at room temperature and subsequently neutralized with 100 mM Tris-HCL,
pH 8.0. After wash with PBS, blocking solution (1% BSA in PBS) was added for 30 min
at room temperature followed by incubation with anti-FLAG antibody (1:1000, Sigma,
F1840) or anti-5-OH-methylcytosine antibody (1:2000, Active Motif, 39770) overnight at
4°C. Secondary antibodies coupled with ALEXA FLUOR® 488 or Cy3 (Invitrogen)
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were used to detect fluorescence signal. After wash with PBS, samples were stained in
DAPI for 30 s and mounted in Prolong Gold antifade reagent (Invitrogen, P36934).
Cytosine modification measurement by LC-ESI-MS/MS system: DNA hydrolysis was
performed as previously described (Song et al., 2005). Briefly, one microgram of
genomic DNA was first denatured by heating at 100 oC. Five units of Nuclease P1
(Sigma, Cat # N8630), was added and the mixture incubated at 37 oC for 2 hours. A 1/10
volume of 1 M Ammonium bicarbonate and 0.002 units of venom phosphodiesterase 1
(SIGMA, Cat # P3243) were added to the mixture and the incubation continued for 2
hours at 37 oC. Next, 0.5 units of Alkaline phosphatase (Roche, Cat # 108138) was
added and the mixture incubated for 1 hour at 37 oC. Before injection into an Agilent
zorbax 4.6mmx50mm, 3.5um particle size -c18 column, the reactions were diluted with
water to dilute out the salts and the enzymes. LC separation was performed at a flow rate
of 220 L/min. Quantification was done using a LC-ESI-MS/MS system in the multiple
reaction monitoring (MRM) mode as described (Song et al., 2005).
AML patient samples and sequence analysis: AML blasts, which had been enriched
from either peripheral blood or bone marrow samples by Ficoll centrifugation and frozen
viable, were obtained from the ECOG sample bank. Samples were analyzed under light
microscopy and found to be >90% blasts after thawing. The ECOG’s Cytogenetic
Subcommittee reviewed conventional chromosome studies that were obtained by
individual institutions and categorized patients as having a risk profile that was favorable,
unfavorable, intermediate, or indeterminate on the basis of a published classification
system. All patients were tested centrally for the most common AML molecular
aberrations, including the mixed-lineage leukemia gene (MLL), partial tandem
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duplication (PTD), and FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication
(ITD), with the use of a semiquantitative polymerase-chain-reaction (PCR) assay.
Genomic DNA was extracted from bone marrow and/or peripheral blood mononuclear
cells from AML patients in the ECOG 1900 cohort at diagnosis. High-throughput DNA
sequence analysis was used to screen for FLT3, NPM1, CEBPA, H/K/NRAS, KIT, WT1,
TET2, ASXL1, IDH1/2, TP53, RUNX1, PTEN, and PHF6 in pre-treatment genomic
DNA. All DNA samples were whole genome amplified using Ø29 polymerase and
mutations were validated on unamplified DNA to ensure all mutations were present in the
diagnostic sample. We performed high throughput PCR amplification followed by DNA
sequence analysis using an ABI 3730 capillary sequencer (Agencourt Bioscience,
Beverly, MA).

Bidirectional sequence traces were analyzed for mutations using

Mutation Surveyor (Softgenetics, Inc., State College, PA), and all traces with putative
mutations were reviewed manually. Samples with missense alleles reported as germline
alleles in dbSNP (dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP) were censored
from analysis. Mutations were scored as somatic based on sequence analysis of matched
remission DNA or based on prior paired sample sequencing demonstrating specific
alleles are somatic; missense alleles which could not be shown to be somatic were
censored from analysis; as with previous studies all frameshift and nonsense alleles were
somatic in origin. All somatic mutations were validated by resequencing non-amplified
source DNA for the particular amplicon where the mutation was noted. Visual
representation of sequencing data for TET2 and IDH1/2 mutations was performed by
creating a Circos diagram.
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Histone extraction and Western blotting: For histone acid-extraction, cells were lysed
in hypotonic lysis buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT,
protease inhibitors) for 1 h. H2SO4 was added to 0.2 N for overnight at 4oC with rotation.
After spinning down and collecting supernatant, proteins were precipitated in 33% TCA,
washed with acetone, and resuspended in deionized water. For whole cell lysate, cells
were lysed in standard RIPA cbuffer (1% NaDOC, 0.1% SDS, 1% TritonX-100, 0.01 M
Tris pH 8.0, and 0.14 M NaCl), and lysates were then centrifuged at 14,000 g at 4ºC.
Supernatants were collected and normalized for total protein concentration, then
separated by SDS-PAGE, transferred to nitrocellulose membrane, blocked in 5% non-fat
milk in PBS-0.5% Tween-20, and probed with primary antibodies, and detected with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (GE
Healthcare, NA934V and NA931V).

Primary antibodies used include: anti-IDH1

(Proteintech, 12332-1-AP), anti-IDH2 (Abcam, ab55271), anti-GST tag (Millipore, 05311), anti-H3K9me2 (Cell Signaling Tech, 9753), anti-H3K9me3 (Abcam, ab8898), antiH3K36me3 (Abcam, ab9050), anti-H3K27me3 (Millipore, 17-622), anti-H3K4me3
(Millipore, 17-614), anti-H3K79me2 (Cell Signaling Tech, 9757), anti-KDM4C (Abcam,
ab85454), anti-acetyl H3 (Upstate, 06-599), anti-H3 (Cell Signaling Tech, 4499), antitubulin (Sigma, T9026), anti-GFAP (Cell Signaling Tech, 3670), anti-β3-tubulin (Cell
Signaling Tech, 5666), anti-p85 (Millipore, 06-195), anti-nestin (Millipore, MAB5326),
anti-β-actin (Sigma, A5316), anti-cyclin D1 (EMD, CC12), anti-p27 (Santa Cruz
Biotechnology, sc-1641), anti-N-cadherin (Cell Signaling Tech, 4061), anti-Collagen I
(Abcam, ab21286), anti-Collagen IV (Abcam, ab6586), anti-BiP (Cell Signaling Tech,
3177), anti-CHOP (Cell Signaling Tech, 2895) and anti-HIF1α (Cayman Chemical,
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10006421). Anti-IDH1 R132H mutant antibody was a kind gift from Agios
Pharmaceuticals. Quantification of Western blot band intensity was performed using
Image J software according to manufacturer’s instruction.
Metabolite extraction and GC-MS analysis: After gentle removal of culture medium,
cells were rapidly quenched with ice cold 80% methanol and incubated at -80ºC for 20
min. Following sonication, extracts were then centrifuged at 14,000 g for 20 min at 4ºC
to remove precipitated protein, and the aqueous metabolites in the supernatant layer were
dried under nitrogen gas. For GC-MS analysis, dried extracts were redissolved in a 1:1
mixture

of

acetonitrile

and

N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide

(MTBSTFA; Regis) and heated for 75 min at 70ºC to derivatize metabolites. Samples
were then injected into an Agilent 7890A GC with an HP-5MS capillary column,
connected to an Agilent 5975 C mass selective detector operating in splitless mode using
electron impact ionization with ionizing voltage of -70 eV and electron multiplier set to
1060 V. GC temperature was started at 100ºC for 3 min, ramped to 230ºC at 4ºC/min
and held for 4 min, then ramped to 300ºC and held for 5 min. Mass range of 50-500 amu
was recorded at 2.71 scans/s. Identification of the 2HG metabolite peak was confirmed
using standards obtained from Sigma. 2HG and glutamate signal intensities were
quantified by integration of peak areas.
Flow cytometry: For cell surface staining of C-Kit, 1 x 106 32D cells were used for each
condition. After wash with PBS, cells were incubated for 15 min with anti-C-Kit
antibody conjugated with APC (1:100, BD Biosciences, 553356). Cells were then washed
3 times in PBS and analyzed by Becton Dickinson Calibur flow cytometer.

For

intracellular staining of FLAG and 5-OH-methylcytosine, 5 x 106 293T cells were used
85

for each condition. After wash with PBS, cells were fixed with paraformaldehyde (3%)
for 10 min at room temperature and permeabilized with 0.5% Triton X-100 for 10 min.
Cells were then treated with 2N HCL for 20 min at room temperature and subsequently
neutralized with 100 mM Tris-HCl, pH 8.0. After wash with PBS, cells were incubated
with anti-FLAG (1:200) and anti-5-OH-methylcytosine (1:400) antibodies for 30 min at
room temperature. After wash with PBS, cells were incubated with secondary antibodies
coupled with ALEXA FLUOR® 488 or Cy5 (Invitrogen) for 30 min in the dark. Cells
were then washed 3 times in PBS and analyzed by Becton Dickinson Calibur flow
cytometer. Data analysis was done using CellQuest.
For FACS analysis of cell cycle distribution, adherent cells in a six-well plate were
trypsinized and collected in 15-ml centrifuge tubes. The collected cells were fixed by
ethanol (final concentration of 70%) overnight at -20 ºC. Cells were then stained with 50
µg/ml propidium iodide (Sigma) with 0.1 mg/ml RNase A for 40 min at 37 ºC. After
washing with PBS, the DNA content of the stained cells was then analyzed by Becton
Dickinson Calibur flow cytometer.
Glioma patient samples, mutational analysis, microarray and gene ontology
functional analysis: Primary oligodendroglioma samples were obtained with approval
from the institutional review board at the University of Pennsylvania and were deidentified for the study. For microarray analysis, tumor sample RNA was extracted with
Trizol and purified with Qiagen RNeasy, and then assayed on an Affymetrix Human
Gene 1.0ST array. "Significance Analysis of Microarrays" (http://wwwstat.stanford.edu/~tibs/SAM/sam.pdf) was applied to find differentially expressed genes
(q-value < 10% and fold-change >2). Functional analysis of differentially expressed
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genes was done using the DAVID tool (http://david.abcc.ncifcrf.gov/home.jsp) using all
human genes as a background set.
For IDH mutation analysis, tumor genomic DNA was extracted and the regions
surrounding IDH1 codon 132 and IDH2 codons 140 and 172 were amplified by PCR
followed by sequencing. IDH1 analysis used forward primer 5’ACCAAATGGCACCATACGA-3’ and reverse primer 5’TTCATACCTTGCTTAATGGGTGT-3’ for amplification, and primer 5’CGGTCTTCAGAGAAGCCATT-3’ for sequencing1. IDH2 analysis used forward
primer 5’-CAGAGACAAGAGGATGGCTAGG-3’ and reverse primer 5’GTCTGCCTGTGTTGTTGCTTG-3’ for amplification, and the same forward primer for
sequencing27. Out of the 42 tumors analyzed, 41 had sufficient high quality genomic
DNA for discerning IDH mutation status. The one sample unable to be classified as
either IDH wild-type or mutant was excluded from further analysis.
Cell differentiation and Oil-red O staining: 3T3-L1 cell differentiation and Oil-red O
staining were carried out as described previously (Wellen et al., 2009). In brief, confluent
3T3-L1 cells were stimulated with a cocktail containing 0.5 mM isobutylmethylxanthine,
1 µM dexamethasone, 5 µg/ml insulin, and 5 µM troglitazone (all from Sigma) in
DMEM with 10% FBS, to induce differentiation. Cells were maintained in DMEM with
insulin after two days of differentiation until ready to be harvested. For Oil-red O staining,
cells were washed in PBS and then fixed for 20 min at room temperature with 3%
paraformaldehyde. Cells were then washed with deionized water and stained with Oil-red
O solution. For quantification, O-red O staining was dissolved in isopropanol and
absorbance was measured at 500 nm.
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Adipocyte differentiation of 10T1/2 cells was done following the same procedure as 3T3L1 cells. Chondrocyte differentiation of 10T1/2 cells was performed as previously
described (Mikami et al., 2011). In brief, confluent 10T1/2 cells were stimulated with a
cocktail containing DMEM with 1% FBS, 10 μg/mL human insulin (Sigma), 3 × 10−8 M
sodium selenite (Sigma), 10 μg/mL human transferrin (Sigma), 10−8 M dexamethasone,
and 100 ng/mL rhBMP-2 (R&D system). Medium were replaced with fresh cocktail
every 2-3 days until cells were ready to be imaged or harvested.
In vitro histone demethylase assay: The histone demethylase assay was carried out as
described previously (Ingvarsdottir et al., 2007). In brief, 4 µg bulk calf thymus histones
(Sigma) were incubated with GST-tagged KDM4C (1.42 µg, BPS Bioscience) in a
reaction mix containing 50 mM Tris-HCl pH 8.0, protease inhibitors cocktail, 1 mM αKG,
100 µM FeSO4 and 2 mM ascorbic acid at 37 °C for 4 h, in the absence or presence of
various concentrations of D-2HG or L-2HG (Sigma). Reaction mixtures were analyzed
by Western blotting using specific antibodies.
Quantitative real-time PCR: RNA was isolated using Trizol (Invitrogen). After
incubating with DNase, cDNA was synthesized using Superscript II reverse transcriptase
(Invitrogen). Quantitative PCR was performed on a 7900HT Sequence Detection System
(Applied Biosystems) using Taqman Gene Expression Assays (Applied Biosystems).
Gene expression data was normalized to 18S rRNA.
Chromatin immunoprecipitation assay: Chromatin immunoprecipitation assay was
performed with Millipore Magna ChIPTM G kit (Millipore, 17-611). In brief, two million
cells were cross-linked with 1% formaldehyde for 10 min at room temperature. After
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washing with cold PBS, cells were centrifuged and lysed in 500 µl SDS lysis buffer for
10 min on ice. Lysate was then sonicated using Bioruptor® sonicator (Diagenode) to
shear DNA to approximately 200-600 bp. Samples were spun down and 50 μl of the
supernatant were used for each immunoprecipitation overnight with magnetic beads after
10 x dilution. Primary antibodies (3 µg per ChIP) used were: anti-H3K9me3 (Abcam,
ab8898) and anti-H3K27me3 (Millipore, 17-622). Normal rabbit IgG (Millipore, 12-370)
was used as control and showed minimal enrichment. The next day, samples were
washed in low salt immune complex buffer, high salt immune complex buffer, LiCl
immune complex buffer, and TE buffer. Histone complexes were eluted in elution buffer
plus proteinase K for 2 h at 65ºC. DNA was recovered using columns. Quantitative PCR
was performed on purified DNA samples. Primers used are: Adipoq forward: 5’ATGGCTGAACCACACAGCTTCA-3’, reverse: 5’AGGGGTCAGGAGACCTCCCTTT-3’; Cebpa forward: 5’CTGGAAGTGGGTGACTTAGAGG-3’, reverse: 5’GAGTGGGGAGCATAGTGCTAG-3’. Data points (Ct) are converted to percentage of
input.
Quantitative DNA methylation analysis by MassARRAY EpiTyping: Matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry using EpiTyper by
MassARRAY (Sequenom) was performed on bisulfite-converted DNA extracted from
3T3-L1 cells. MassARRAY primer design was done as previously described (Figueroa et
al., 2009).
Immunohistochemistry: The immunohistochemistry detection was performed using
Discovery XT processor (Ventana Medical Systems). The tissue sections were blocked
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for 30 min in 10% normal goat serum in 0.2% BSA/PBS, followed by incubation for 5 h
with 0.1 µg/ml of the rabbit polyclonal anti-H3K9me3 (Abcam, ab8898) or 1 µg/ml
rabbit polyclonal anti-H3K27me3 (Millipore, 07-449) antibodies and incubation for 60
min with biotinylated goat anti-rabbit IgG (Vector labs, PK6101) at 1:200 dilution. The
detection was performed with DAB-MAP kit (Ventana Medical Systems). The entire
slides were scanned by Zeiss Mirax Scan (Carl Zeiss) using 20x/0.8 objective. The
scanned image was exported into image analysis software, Metamorph (Molecular
Devices). Color threshold for DAB-positive nuclei was determined and set for all images.
Areas above threshold for DAB signal and for hematoxylin-counter stained total nuclei
were measured in an automated fashion. Ratio between the two parameters were
calculated and analyzed for statistical significance.
Synthesis of 1-octyl-D-2-hydroxyglutarate: Commercial R(-)-tetrahydro-5-oxofuran-2carboxylic acid (140 mg, 1.076 mmol) was dissolved in H2O (1 ml), cooled to 0oC and
treated with 1 N KOH (2.16 ml, 2.15 mmol). The resulting solution was stirred at this
temperature for 5 min and at ambient temperature for 2 h. It was then concentrated to
dryness under reduced pressure and dried. The residue was dissolved in trifluoroacetic
anhydride (8 ml) at 0oC, stirred for 30 min at 0oC, 2 h at room temperature, then the
volatiles were evaporated under reduced pressure. The residue was dried and dissolved
in anhydrous tetrahydrofuran (6 ml). Octanol (0.3 ml, 2.1 eq.) was added to the solution
at 0oC and the mixture was stirred for an overnight period at ambient temperature. Water
was added to quench the reaction, and the mixture extracted with EtOAc. The combined
extracts were dried over MgSO4, concentrated and purified by Flash chromatography
(EtOAc/Hexane 1:3 and 1:1) to give 1-octyl-D-2-hydroxyglutarate (110 mg, 39%).
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Neurosphere isolation, culture and differentiation: Six days postpartum Ink4a/Arf null
(p16/p19-/-) mice were sacrificed with the isolated subventricular zones subjected to
chemical (Pronase E, Calbiochem 7433-2) and mechanical dissociation to obtain a single
cell suspension in full neurobasal medium (Neurobasal medium, GIBCO 21103; B27
supplement without retinoic acid, GIBCO 12587-010; Glutamax, GIBCO 35050; 20
ng/mL EGF, R&D Systems 236-EG; 20 ng/mL basic FGF, Millipore GF003). On the
next day the cells were spun down and re-suspended in fresh medium, and once
neurospheres had formed in culture, the spheres were collected and chemically
dissociated (Accumax, Innovative Cell Technologies AM105) back into single cells in
fresh medium.
One day after final infection, infected neurospheres and a non-infected control were
placed in 400 µg/mL Hygromycin B (InvivoGen, ant-hg-1). Once selection was complete,
isogenic cell lines maintained in full neurobasal medium were chemically dissociated into
single cells and were plated at the same density in full neurobasal medium with
increasing concentrations of retinoic acid (Sigma-Aldrich, R2625). 72 h later cells were
harvested, and expression of proteins was analyzed by Western blotting.
Measurement of total CpG methylation: DNA methylation was assessed as previously
described (Habib et al., 1999). In brief, 1 x 106 NHA cells were washed with PBS and
fixed with 2% paraformaldehyde for 10 min at room temperature and permeabilized with
0.5% Triton X-100 for 10 min. Cells were then treated with 2 N HCL for 20 min at room
temperature and subsequently neutralized with 100 mM Tris-HCl, pH 8.0. Cells were
incubated with anti-5-methylcytosine antibody (Calbiochem, NA 81) at 1:100 dilution for
30 min at room temperature. After washing with PBS, cells were incubated with
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secondary antibody coupled with ALEXA FLUOR® 488 (Invitrogen) for 30 min in the
dark. Flow cytometry was done using Becton Dickinson Calibur flow cytometer and
analyzed using FlowJo software.
Tumor xenograft study: 10T1/2 cells were harvested with trypsin and resuspended in
PBS. About 107 cells were injected s.c. into both flanks of 6-8 weeks old athymic female
nude mice (Jackson Lab). Formation of tumors was monitored. After tumors became
palpable, tumor volumes were estimated by caliper measurements assuming spherical
geometry (volume = d3 × π/6).
Extended reduced representation bisulfite sequencing (ERRBS): Genomic DNA was
extracted from 10T1/2 cells with Qiagen Gentra Puregene kit. ERRBS was performed
with 25-50ng genomic DNA as described previously (Akalin et al., 2012).
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